The Next 25 Years
Beginning the End of Cancer
About the Cover
PCF’s research is responsible for catalyzing progress across innovative treatments that were not available 25, 10, or even 2 years ago — including gene targeted therapies, immunotherapy, radiopharmaceuticals, and microbial transplants. The next 25 years will see rapid change in the way we view and treat cancer.

The Next 25 Years
Beginning the End of Cancer

Mission Statement
PCF funds the world’s most promising research to improve the prevention, detection, and treatment of prostate cancer and ultimately cure it for good.

Beginning the End of Cancer
25 years at the forefront of bleeding edge cancer research affords a lot of perspective. With more than 1.5 million more men alive today because of PCF’s innovative cure model, we have earned the right to look forward, and here’s what we see: this is the beginning of the end of cancer.

It has been a long fight – a valiant fight – with many plot twists and turns. So, you might ask, what’s suddenly different?

Investments in big data and global information sharing are bringing together great minds to collaborate in ways they never could have imagined. This convergence allows PCF not only to learn from research across all cancer, but to bring treatments to market that go beyond prostate cancer and into more than 73 other forms of human cancer.

The fight is not over, but inside you’ll find many of the reasons why we think the final chapter has begun.
The Next 25 Years
Beginning the End of Cancer

The Flexibility to Fail: A New Way to Succeed in Cancer Research
A Message from our Chairman and CEO 4

PSMA Theranostics: “If We Can See It, We Can Treat It” 7

Many vs Cancer 2018 Impact: The Power of Many 10

PCF+Fuego Box: How a Spicy Chocolate Bar is Saving Mankind 12

2nd Annual PCF TRUE Love Campaign 14

PCF Partners With the Atlanta Hawks for Black History Month Assist Challenge 15

NIH and PCF Partner to Launch Research Study on Prostate Cancer in African American Men 16

New Game-Changing Drugs for Advanced Prostate Cancer 18

The John and Daria Barry Foundation Precision Oncology Center of Excellence at the VA New York Harbor Healthcare System 20

2018 PCF New York Dinner at Daniel 21

The Movember Foundation and PCF Celebrating More Than a Decade of Partnership 22

The Inaugural Jerry Weintraub Celebrity Pro-Am Golf Tournament 23

Another Year Around the Bases for the 2018 Home Run Challenge 24

Never Give Up: The Journey From Metastatic to Complete Response 26

Supporting Cures 29

2018 Donor Roll 30

2018 Research Awards Expanding PCF’s Global Research Enterprise 36

2018 Financials 42

2018 Supporting Partners 46

Board of Directors and Leadership Team 47
The Flexibility to Fail
A New Way to Succeed in Cancer Research

Dear friends,

In 1993, nearly 35,000 men in the United States died from prostate cancer. If you had advanced disease, there were few treatments available, and even those men whose disease was caught early suffered major and sometimes permanent changes in quality of life for both themselves and their families.

Today, thanks to your support and 26 years of cutting-edge research by the Prostate Cancer Foundation, life for men with prostate cancer looks entirely different. There are more than 20 drug choices available for men with advanced disease, and many more treatment options are in the pipeline. Without the rapid-funding model pioneered by PCF, many of these discoveries might still reside in research rather than in clinical settings.

Here are 10 more revolutionary ways PCF continues to shake things up in the research world so that we can catalyze progress, innovate, and deliver the best treatments for patients and families:

1. We actively bring together the world’s best and brightest, working on the most promising ideas.
2. We lead prostate cancer out of the shadows and into the forum of public discussion.
3. We actively require researchers to share unpublished data with each other.
4. We have been transparent with every dollar we spend – even before transparency was trendy.
5. We have always given scientists the flexibility to fail in order to succeed boldly.
6. We reward nimble, entrepreneurial behavior and speed progress.
7. We fund interdisciplinary teams of scientists – across institutions and continents – who make innovative drugs that drug companies couldn’t even conceive of.
8. We invest in brilliant, yet unknown, young researchers with the most game-changing ideas and fearless drive to help patients.
9. We attract and catalyze mutually beneficial partnerships among government, biopharma, academia, and other foundations.
10. We’ve begun to democratize the delivery of precision healthcare. For all the problems the internet has created for medicine – not the very least of which is the dissemination of false information – there’s one amazing feature that supersedes all of its shortcomings combined: PCF has been able to scale and speed the development and delivery of precision treatments to patients. We can now put the best, most accurate “PCF-blessed” information about care options directly into the hands of patients who previously might not have had access.

PCF has always approached prostate cancer as a disease that affects families: caring for men with prostate cancer means looking out for the entire family. Thanks to prostate cancer research that you have funded, we now know that some of the most aggressive prostate cancers are based on genetic mutations that cross over to other forms of cancer. Just one example: if you have prostate cancer, your daughter may be at increased risk for breast cancer. That’s critical information for patients and families to know, and crucial work for PCF to fund.
Here are 10 of the top investments from the PCF Research Enterprise that promise to make a difference in prostate cancer patients’ lives in 2019 and beyond:

1. **Precision Radiopharmaceuticals.** PSMA is a protein that lives on the surface of all prostate cancer cells, and we’re learning how to use it as a homing device. PCF is studying radioactive molecules which, when injected into the bloodstream, can seek out and destroy dangerous cancer cells while leaving normal cells alone.

2. **Checkpoint Immunotherapy.** PCF was an early supporter of Nobel Prize winner Jim Allison’s work to bring checkpoint immunotherapy to solid tumors. The full benefit of this critical immunotherapy has yet to be seen in prostate cancer, so look for more trials on the horizon.

3. **Natural Killer Cells.** NK cells, i.e. natural killer cells, can kill thousands of chemotherapy-resistant cancer cells (many more than a CAR-T cell can). They are part of the innate immune system, traveling around the body taking out “stressed” cells, such as cancer. PCF researchers are looking at cost-effective ways to isolate, grow, and transfer colonies of these cells – in a directed way – into the body. Our aim is to genetically engineer or “program” these cells to better target cancer.

4. **Microbiome.** There are 30 trillion cells in your body, but there may be as many as 100 trillion microorganisms living in and on your body. Science is revealing that for cancer treatment (particularly immunotherapy) to be maximally effective, the 100 trillion organisms – referred to as your microbiome – must be in harmony. PCF is investing in precision nutrition research to optimize the care and feeding of your microbiome.

5. **Dark DNA.** For years scientists have been focusing on the “hardware” of cancer: the genes themselves. Dark DNA refers to the software that runs the system; it is inherited from your parents and provides scientists with clues to which people may be more likely to develop cancer. Researchers are discovering that they can do more damage to cancer by tweaking the software code rather than the hardware itself.

6. **Microelectronic Noses that Sniff Out Prostate Cancer.** Dogs are able to smell prostate cancer at a sensitivity that is 10 times more effective than our current PSA blood test. PCF has teamed with scientists at MIT to investigate the possibility of developing a robotic nose to detect prostate cancer at a very early stage.
7. **AI for Big Data at the VA.** Prostate cancer is the most common disease among our nation’s heroes: veterans. PCF and the VA are partnering to prevent, screen, and promote research to speed the development of treatments and cures for prostate cancer among veterans. The wealth of electronic data collected in this program will have an extraordinary impact across the entire field of prostate cancer research – involving hundreds of thousands of patients – and beyond.

8. **Neuronal Protection to Reduce Erectile Dysfunction.** Trauma to the body can cause tissue damage. Fortunately, with prostate cancer surgery, we know when the trauma is going to take place (unlike, say, in the case of a stroke), and we know exactly what tissue area will be affected. Researchers are looking into what preventive action might be taken to strengthen and preserve the nerves around the penis before surgery.

9. **Liquid Biopsy.** A PCF Challenge Award team is developing a “liquid biopsy” blood test to assess tumor mutations, replacing the need for invasive, painful, and expensive biopsies of tumors. Results from this test could revolutionize predictions of tumor recurrence and patient prognosis.

10. **Precision Treatment Across Cancer Types.** Unique cancers in unique patients require unique cures. The recent advent of affordable genetic sequencing panels, combined with the cutting-edge innovations listed above, means that the research that PCF has been doing for years – to identify gene targets and develop targeted treatments for prostate cancer – can finally be put to good use. It also means that a drug developed for prostate cancer could be equally useful, if not more so, in colon, breast, lung, or any number of other cancers and has the potential to impact millions of lives.

Twenty-six years ago when PCF was launched, many of the ideas above might have been found in a sci-fi movie. Today and in the years to come – thanks to your generosity – we’re seeing medicine so revolutionary that science is finally catching up to our imaginations.

The complete elimination of death from prostate cancer continues to be our goal, and we are in a race against time for every patient and his loved ones. New treatments are on the horizon, but we still need your help to finish the job. With your support and the innovative ideas of brave investigators that have led us this far, we are hopeful that we will extend and save the lives of millions.

With gratitude,

---

Michael Milken  
*Founder and Chairman*

Jonathan W. Simons, MD  
*President and Chief Executive Officer*
PSMA (prostate-specific membrane antigen), is a protein that is expressed on the surface of prostate cancer cells. Because of its properties, PSMA is considered one of the most promising targets for both imaging and treating prostate cancer. **PSMA theranostics** is an emerging field of medicine that combines precise imaging and very specific therapy, using the same molecular target – and the Prostate Cancer Foundation has been involved in this exciting research from the very beginning.

**What is Theranostics?**

Theranostics is a new field of medicine that combines specific targeted therapies based on specific targeted diagnostic tests. With a key focus on patient-centered care, theranostics provides a transition from conventional medicine to a contemporary, personalized, and precision medicine approach.

The theranostics paradigm involves using nanoscience to unite diagnostic and therapeutic applications to form a single agent, allowing for diagnosis, drug delivery, and treatment response monitoring.
In 1996, PCF-funded scientist and Weill Cornell Medicine physician Neil Bander, MD created an antibody that can target PSMA, and in a series of clinical trials, demonstrated that when attached to a radioactive molecule, this agent could be used to both image and treat prostate cancer. In 2002, a Johns Hopkins team led by another PCF-funded investigator, Martin Pomper, MD, PhD, developed a similar weapon: a PSMA-targeting small-molecule imaging agent. In 2011, with PCF and Movember funding, Pomper’s colleague, Steve Cho, MD, now at the University of Wisconsin, led the first human PET imaging study using Pomper’s agent and found that it was especially good at picking up high-grade Gleason tumors within the prostate – something that men considering active surveillance or treatment for localized cancer really need to know.

Since then, PSMA-PET imaging using a derivative of this small molecule, 18F-DCFPyL, also developed by Pomper, and with a similar agent developed at the University of Heidelberg in Germany, 68Ga-PSMA-11, has been shown to outperform all standard imaging methods for detecting metastatic prostate cancer. These tests can identify very small sites of metastasis that may not show up on CT or bone scans. The ability of PSMA-PET to detect metastatic or recurrent disease earlier could shift additional treatment earlier, as well. Depending on whether the spread of cancer is localized, “oligometastatic” (just a few spots of cancer outside of the prostate), or more widespread, treatment may be aimed at specific locations – via salvage radiation, salvage pelvic lymph node removal, or stereotactic body radiation therapy (SBRT) – or may involve systemic therapy.

For example, Johns Hopkins University radiation oncologist and PCF-funded investigator Phuoc Tran, MD, PhD, hypothesizes that in men with oligometastasis, by treating “not only the primary disease in the prostate or the pelvis, but also the few metastatic lesions, perhaps men can actually live a long time without disease progression, and might even be cured.” Using PSMA-PET to show spots of cancer
as small as a few millimeters, SBRT can deliver “highly focused radiation given in an intense fashion,” Tran says. “I tell patients it’s like spot welding: focused on a small area, very intense, and theoretically ablative, meaning it kills all the cancer in that spot.” Tran is testing this hypothesis in a randomized clinical trial.

PCF-funded investigators including Kenneth Pienta, MD, Steven Rowe, MD, PhD, and Mark Markowski, MD, PhD, of Johns Hopkins University; Michael Morris, MD, and Steven Larson, MD, of Memorial Sloan Kettering Cancer Center; Steve Cho, MD of University of Wisconsin; Mark Preston, MD, of Harvard: Brigham and Women’s Hospital: Thomas Hope, MD, of the University of California, San Francisco; and Johannes Czernin, MD, of the University of California, Los Angeles, are now leading pivotal registrational clinical trials for the PSMA-PET imaging agents 18F-DCFPyL and 68Ga-PSMA-11. It is likely that FDA approval will be granted in the very near future for these agents.

Equally exciting, is that when PSMA-targeted agents are hooked up to more powerful radioactive isotopes (those that emit DNA-damaging alpha or beta particles), they become potent cancer therapies. **PSMA-targeting radionuclides** can bring a high dose of radiation directly to cancer cells anywhere in the body, with the potential to kill them. Several different PSMA-targeted radionuclide therapies developed by PCF investigators and others are being tested in clinical trials for prostate cancer. Early reports on these treatments have been highly promising. Radionuclides using Bander’s antibody (J591) for instance, have demonstrated both safety and promising efficacy and continue to be tested in several trials. Another of these agents, 177Lu-PSMA-617, cut PSA levels by half or more in 62% and 33% of patients in two separate Phase II clinical trials led by PCF-funded investigators Michael Hofman, MD, at Peter MacCallum Cancer Centre in Australia, and Jeremie Calais, MD, at the University of California, Los Angeles, respectively. In these trials, 10%-15% of patients were considered “exceptional responders,” with PSA or tumor burden going almost entirely to zero, although no patients were cured. 177Lu-PSMA-617 has now advanced to testing in an international, multicenter, randomized Phase III trial.

PCF is funding numerous investigations into developing and optimizing this new class of treatments, testing them in combination with other treatments and identifying which patients are most likely to benefit and why. PSMA-PET imaging, as it turns out, is likely ideal for identifying which patients are more likely to respond to PSMA-targeted therapies, and is being used to select patients for clinical trials. As Howard Soule, PhD, Executive Vice President and Chief Science Officer of PCF, puts it: “If we can see it, then we can treat it.”

Radioactive isotopes are not the only payload that can be delivered directly to prostate tumors by PSMA-targeting agents. PSMA-targeting treatments that deliver cancer-killing immune cells or chemotherapy are also being developed. For instance, PSMA-targeted CAR T cells have been developed by PCF-funded investigators at the University of Pennsylvania and are now in Phase I clinical trials.

Over the past 25 years, PCF has invested more than $15.8 million in investigations into PSMA as a target for prostate cancer treatment or imaging.
Many vs Cancer

Through this grassroots group of caregivers, survivors, family, friends, and fighters, we have raised more than $1.5 million to defeat prostate cancer once and for all.

One observation we often hear from families who have been affected by cancer is “I feel powerless against this disease. What can I do to help?” Many vs Cancer was founded on the idea that anyone and everyone can make a difference in the fight against cancer. MvC helps bring awareness to each of our social circles and provides easy to use tools to activate your network in support of prostate cancer research. To date, funds have been raised from efforts like backyard parties, lemonade stands, running, cycling, and other events like the PCF Pushup Challenge.

Please visit manyvscancer.org today and join our community.

Here are some of our superstar fund raisers for 2018:

Ramiro Siliezar
Ramiro is an LA-based custodian with a passion for running. After his twin sister was diagnosed with BRCA+ breast cancer, Ramiro decided to dedicate his runs to her and to start fundraising for cancer research. When he learned that the BRCA gene is also an area of focus for the Prostate Cancer Foundation, Ramiro joined Many vs Cancer and started inviting friends, family and local business professionals to support him. To date, he has run over 1,000 miles for PCF, raising nearly $70,000.
David Frantz (pictured left)
David, a retired high school golf coach, was voted “Coach of the Year” three times, but he could have never anticipated that he and his older brother, Will, would both be diagnosed with prostate cancer. Will lost his life to the disease, which lit a fire under Dave to help fund PCF’s research. While getting ready to undergo surgery, Dave set up his page and rallied friends together to raise more than $2,400.

Milton High School Cross Country Team
Each year, the Milton High School Cross Country Team tasks its captains with selecting a charity to support. After learning that one of their coaches and two fathers of team mates were diagnosed with prostate cancer, it was an easy decision. The team raised $7,159, beating their $7,000 goal. Go Eagles!

Steven Malikowski
Steven, a former Education Program Specialist with the Department of Family Medicine and Community Health at the University of Minnesota, is living with advanced prostate cancer and being treated with a drug that was developed with PCF funding. He wanted to give back to the Foundation and his lifelong dream has been to cycle across the continental U.S. This year, he did it! Starting at the Virginia coastline, Steven cycled over 4,100 miles, crossing mountains, plains and everything in between. After four months on the road, he dipped his front tire in the Pacific Ocean and celebrated the completion of his ride. Through his journey, Steven raised more than $4,500.

It takes more than one person to end prostate cancer.
It takes many.
Fuego Box, the world leader in craft hot sauce subscription boxes, specializes in curating and delivering the most delicious and hard to find hot sauces to chili heads around the world. After successfully launching a Father’s Day Gift Box benefitting PCF in 2018, Fuego Box realized that their customers (and prospective customers) care about prostate cancer and were responding to the company’s support of men’s health. Building off this success, Fuego Box’s Founder and Co-Owner, Mike McAdams, partnered with PCF to launch The Choco Challenge.

The Choco Challenge
The concept was simple, elegant, effective, and fun: Create the world’s spiciest mini-chocolate bar and then challenge the public to purchase the bar and film themselves eating it – with $5 of every purchase donated to PCF.

Why it Worked
The internet is rife with “spicy challenges”, but this was the first time that one incorporated a charitable cause and included a men’s health education and awareness message. Many responded to the “dare” of eating something so spicy, while many others tuned in for the entertainment and schadenfreude of watching someone take the challenge.

PCF Director of Corporate Development, Oliver Freund (center) is presented with a donation check for $125,000 by Fuego Box founder, Mike McAdams (right) and Operations Manager, Teddy Wilkins (left).
The Results

- More than 27,000 Choco Challenge bars sold to spice seekers around the world
- $135,000+ raised in support of PCF’s mission
- $205,000 value of earned media coverage reaching more than 6 million consumers
- 27,000+ Choco Challenge participants educated about prostate cancer via inclusion of PCF’s messaging and educational content with every package sold
- Due to the viral nature of spicy challenges, the top 7 Choco Challenge videos alone generated more than 8 million views.
- User generated videos created and shared across social media platforms were viewed by millions of people, gaining the attention of mainstream celebrities and prime time television.
- Through 10,000+ videos, challenge takers were dedicating their Choco Challenge to fathers, uncles, and grandfathers affected by the disease, with many noting that a few minutes of pain was nothing compared to battling a prostate cancer diagnosis.
- The campaign went viral, catching the eye of several mainstream celebrities. Of note, Shaquille O’Neil highlighted the challenge on Inside the NBA, and Kristen Bell and Dax Shepard had their Choco Challenge video featured on The Ellen Show.

Key Learning: Doing Good is Good for Business

The lesson here is that PCF is always ready for the next innovative idea to share our message and engage the public in a conversation about prostate cancer. We can “do good” for our research mission while also supporting the business and marketing goals of our partners.

Does your company want to join us in our mission? Get in touch with us and we can build the next head-turning, high-impact campaign together!
In February 2019, PCF celebrated the 2nd Annual month-long *TRUE Love* campaign and contest that honored caregivers for their tireless work in caring for loved ones living with prostate cancer.

The campaign was designed to drive greater awareness of PCF by exposing us to new audiences. *TRUE Love* is a tribute to the unsung heroes – spouses, partners, nurses, doctors, siblings, children, and friends. PCF accepted “*TRUE Caregiver Stories*” from all perspectives that reflected love, honor, and care for prostate cancer patients throughout the Valentine’s season when love is celebrated. Those with the most inspirational stories won a special care package personally curated by award-winning actress Kristen Bell, who also served as the spokesperson and face of the campaign.

Kristen, known for her accomplished work in *Veronica Mars*, *Frozen*, and *Bad Moms*, helped create awareness about the *TRUE Love* contest and how a prostate cancer diagnosis affects the entire family. The cause hit close to home for Bell. Her mother is a nurse, and her father-in-law fought prostate cancer and has sadly passed away after a multi-year battle. She understands first-hand how caregivers are an essential part of a support system and how they often lack support and are underacknowledged, compared to caregivers of other diseases. PCF and Kristen changed this narrative by sharing *TRUE* inspirational stories of the people who live *TRUE Love* everyday by providing care to men – many who have debilitating metastatic disease.

We are so grateful to Kristen for helping us raise awareness about prostate cancer with this campaign. Her generosity, authentic compassion, and broad reach played an integral part in the campaign’s success and also helped shine a spotlight on all the resources we have available for patients and their caregivers.
February 2019 launched the first-ever Black History Month Assist Challenge. The Atlanta Hawks teamed up with PCF to be the first NBA team to bring the disparity of prostate cancer rates in African American men to center court.

The Atlanta Hawks donated $250 to PCF for every assist they made in the month of February to fund research that will address the fact that African American men are 76 percent more likely to be diagnosed with prostate cancer, and more than twice as likely to die from the disease.

The spotlight the Atlanta Hawks shined on prostate cancer dramatically increased awareness of this disease. Life-saving information about risks and screening reached more than 120,000 people during the 12 NBA games they played in February and reached hundreds of millions more through digital outreach. Thanks to the Atlanta Hawks, more men of all ethnicities will be screened this year, know their risks, and get the early treatment they need.
July 2018 – The NIH and the Prostate Cancer Foundation have partnered for the largest coordinated research effort in history. The RESPOND study, or Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress, will study how biological and non-biological factors contribute to African American men being diagnosed with prostate cancer at alarmingly high rates relative to other ethnic groups. The reason these disparities exist is a critical unanswered question in cancer research.

African American men are 76% more likely to be diagnosed with prostate cancer, are more likely to develop an aggressive, quickly progressing form of prostate cancer, and are 2.2 times more likely to die of prostate cancer than men with other ethnic backgrounds.

This $26.5 million study will aim to enroll 10,000 African American men with prostate cancer into the RESPOND study. Investigators in the study will examine possible associations between aggressive disease and exposures to neighborhood/environmental stressors such as discrimination, early-life adversity, and segregation. They will also study DNA and tumor samples to identify gene variants associated with aggressive prostate cancer. Once researchers have identified genetic changes associated with aggressive prostate cancer, they will investigate how the social environment interacts with those genetic changes.

RESPOND is supported by the National Cancer Institute (NCI) and the National Institute on Minority Health and Health Disparities (NIMHD), both parts of the National Institutes of Health, as well as by the Prostate Cancer Foundation (PCF). The NCI funding will be provided from the 21st Century Cures Cancer Moonshot Initiative.

“\nNo group in the world is hit harder by prostate cancer than African American men, and, to date, little is known about the biological reasons for these disparities, or the full impact of environmental factors. We celebrate our partnership and applaud NIH for spearheading this study, which we believe will help pave the way for groundbreaking discoveries that will improve health equity for African American men and their families.”

— Jonathan W. Simons, MD
President & CEO, Prostate Cancer Foundation
Drs. Christopher Haiman and John Carpten of USC are two of the many investigators engaged in the RESPOND African American Prostate Cancer Study.

The RESPOND study is supported by the National Cancer Institute and the National Institute on Minority Health and Health Disparities of the National Institutes of Health, under grant number CA214253 and by the Prostate Cancer Foundation.
New Game-Changing Drugs for Advanced Prostate Cancer

Until recently, androgen deprivation therapy (ADT) alone was the front-line treatment option for men with advanced prostate cancer. Unfortunately, nearly all patients will eventually become resistant to ADT, creating an urgent medical need for new treatments.

Fortunately, due in large part to PCF’s funding of crucial basic science research and the early steps of new drug development, the treatment landscape has rapidly evolved over the last two years, with a slew of clinical trials demonstrating that using stronger therapies earlier can be extremely beneficial.

There are now 5 new treatments that demonstrate significant survival benefit or disease progression slowing when used before ADT resistance develops. These include docetaxel chemotherapy and four “second-generation” hormone therapies – abiraterone, enzalutamide, apalutamide, and darolutamide. PCF-funded research pivoted the development of all of these treatments.

Two categories of advanced prostate cancer have benefited from these new therapies:

1. Metastatic prostate cancer that has not yet been treated with ADT (aka metastatic “hormone-sensitive” prostate cancer, mHSPC)

2. Non-metastatic castration-resistant prostate cancer (nmCRPC), a clinical state of rising PSA after ADT and before clinical metastasis is detectable

In mHSPC, the addition of abiraterone or docetaxel at the time men start ADT extended their lives for an average of 17 months in men with high-risk or high-volume metastatic disease. In 2018, the FDA approved abiraterone for men with high-risk mHSPC who were starting ADT. In early 2019,
clinical trial results show that enzalutamide and apalutamide are also effective for mHSPC, and FDA approval is now being sought. It is premature to know which of these treatments is most effective. PCF is funding precision treatment research to answer this question.

nmCRPC was previously a treatment desert without life-prolonging treatments available. These men typically had no other option but to continue taking ADT, despite its diminishing benefit. In 2018, the FDA approved apalutamide and enzalutamide for men with nmCRPC, in combination with ADT. On the horizon is a third option: darolutamide, as results from a Phase III trial have recently been reported as positive. Each of these treatments, when added to ADT, has been shown to delay the onset of metastases by an average of 22–24 months. It is still too early to know if the addition of any of these treatments to ADT in nmCRPC extends survival, but early results hint in that direction.

We at PCF are particularly proud of these new additions to the arsenal of precision treatments for advanced prostate cancer because we helped get these drugs developed. PCF funded the seminal discovery that second-generation hormone therapies could be effective in ADT-resistant prostate cancer – a finding that inspired their development. PCF funded the initial biology and chemistry of both enzalutamide and apalutamide and their early preclinical studies. PCF was instrumental in funding the early stage trial that led to the development of abiraterone, and eventually its FDA approval in 2011. PCF also funded the therapy consortium that conducted early clinical trials for docetaxel which led to its formal development and FDA approval in 2010. We continue to fund research with the promise of finding even more effective treatments for advanced prostate cancer.

“These are very dramatic findings for improving patient care,” says scientist Howard Soule, PhD, PCF’s Chief Science Officer, who directs PCF’s worldwide research programs. However, he adds, “the work is far from over. Every day, men are still dying of prostate cancer. This is why we fund research: to discover cures and to improve quality of life.”

"
Through the generosity of the John and Daria Barry Foundation, PCF’s partnership with the Department of Veterans Affairs continues to expand. On November 8, 2018, PCF held a VALOR Dedication Ceremony honoring hundreds of thousands of courageous veterans living with prostate cancer. During the ceremony, PCF president and CEO, Dr. Jonathan W. Simons, recognized the John and Daria Barry Foundation’s transformational gift of $2.5 million to PCF to establish the John and Daria Barry Foundation Precision Oncology Center of Excellence at the Manhattan Campus of the VA NY Harbor Healthcare System (VANYHHS). This center will address the clinical needs of veterans currently battling prostate cancer in the New York metropolitan area and beyond, delivering precision treatments that are tailored to each patient’s care based on a genetic understanding of their disease. This best-in-class care will be made accessible to veterans to honor the sacrifice of those who have served. The precision oncology and genetic counseling that will be provided in Manhattan will help lead to better treatments and cures for all veterans. This research will advance critical scientific knowledge with broad implications for the medical research community’s ability to deliver life-saving precision treatments and cures to cancer patients globally.

For their groundbreaking philanthropy, the Barry Family accepted a special award and honorary doctors' coats representing the sacred trust between doctor and patients.

Left to right: James Barry, Elizabeth Barry Swanson, John Barry, Daria Becker Barry, Deborah Scher, Martina Parauda, Daria Morgan Barry, and Matthew Barry.

Through the generosity of the John and Daria Barry Foundation, PCF’s partnership with the Department of Veterans Affairs continues to expand. On November 8, 2018, PCF held a VALOR Dedication Ceremony honoring hundreds of thousands of courageous veterans living with prostate cancer. During the ceremony, PCF president and CEO, Dr. Jonathan W. Simons, recognized the John and Daria Barry Foundation’s transformational gift of $2.5 million to PCF to establish the John and Daria Barry Foundation Precision Oncology Center of Excellence at the Manhattan Campus of the VA NY Harbor Healthcare System (VANYHHS). This center will address the clinical needs of veterans currently battling prostate cancer in the New York metropolitan area and beyond, delivering precision treatments that are tailored to each patient’s care based on a genetic understanding of their disease. This best-in-class care will be made accessible to veterans to honor the sacrifice of those who have served. The precision oncology and genetic counseling that will be provided in Manhattan will help lead to better treatments and cures for all veterans. This research will advance critical scientific knowledge with broad implications for the medical research community’s ability to deliver life-saving precision treatments and cures to cancer patients globally.

During the ceremony, Director of the VANYHHS, Martina Parauda, graciously acknowledged U.S. veterans in attendance for their years in service. The VALOR Dedication Ceremony opened with the National Anthem performed by Sergeant Constance Campbell to honor America and the military veterans in attendance. On behalf of the Secretary’s Center for Strategic Partnerships, U.S. Department of Veterans Affairs Executive Advisor to the Secretary, Deborah Lafer Scher made special remarks.
The 2018 Daniel Dinner marked our seventh dinner at the famed Daniel Boulud New York restaurant. Held biennially, the dinner only accommodates 130 people and is a much more intimate experience than our larger New York dinner held on alternate years. Having now established such a long and close relationship with Chef Boulud, he takes great pride in personally creating a special menu for our guests that never disappoints.

The dinner provides an unusual, up-close-and-personal experience with our entertainment. In 2018, The Evasons, a mentalist husband and wife duo wowed our guests with their mind reading skills and powers of perception. Our special musical performer was Pat Benatar. The legendary singer, songwriter, and actress, is the recipient of 4 Grammy awards and has 2 multi-platinum albums, 5 platinum albums, 3 gold albums, and 15 Billboard Top 40 singles in a career that spans nearly 40 years.

The evening also focused on additional funding of PCF Young Investigator Awards, Challenge Awards, and establishing additional Centers of Excellence in association with our partnership with the VA. The evening successfully brought in more than $8 million, including $5 million for 2 new Centers of Excellence and more than $2 million in new Young Investigator and Challenge Awards.
Since 2007, the Movember Foundation has generously donated $56 million to PCF to support 45 research awards in the U.S., Canada, and Great Britain. We are honored to be in the second decade of this incredible partnership which has led directly to many life-prolonging and life-improving oncology developments.

Thanks to Movember funding:

- More than 70 clinical trials testing new prostate cancer treatments and imaging technologies have been initiated
- Clinicians have developed the science and technology necessary for conducting precision medicine in men with metastatic prostate cancer
- New precision medicine treatments have been discovered for patients who have DNA repair gene mutations in their tumor
- The discovery that inherited DNA repair gene mutations increase risk for prostate, breast, ovarian, and other cancers, has led to precision genetic counseling for family members of men with prostate cancer
- A more sensitive new imaging technology, PSMA-PET, has been developed for visualizing prostate cancer recurrences earlier
- Many new drugs have entered the R&D pipeline for treatment-resistant prostate cancer

- Biomarkers, including AR-V7, have been discovered that help doctors to choose the most appropriate treatments for patients
- Blood tests are being developed to analyze tumor mutations so that patients can avoid invasive biopsies of metastatic disease
- Clinical trials are testing new combination treatment strategies that may enable cures in men previously considered to be incurable
- New prostate cancer immunotherapies are being developed, including engineering a patient's own immune cells to fight their cancer

PCF is incredibly grateful to the Movember Foundation for this invaluable partnership.
In December 2018, a not so extravagant, but certainly not subdued party lit up the night and danced on the links of the Madison Club in La Quinta, CA. The event honored a man who not only survived prostate cancer, but generously funded life-saving prostate cancer research. That man was Jerry Weintraub.

His calling wasn’t to promote or manage great musical talent, or produce and direct Hollywood hits... that was his illustrious career. No, his calling was to serve as a lightning rod, bringing joy and building sacred bonds with everyone he met. Regardless of when they parted company, meeting up with Jerry meant tapping straight into that joy as if no time had passed.

The inaugural Jerry Weintraub Celebrity Pro-Am brought out Hollywood celebrities, musicians, active and retired professional athletes, and terrific PGA Tour talent, young and old, to join incredibly supportive donors for a two-day affair never to be forgotten.

Here’s to Jerry and his legacy of giving!
2018 marked Major League Baseball (MLB) and PCF’s 23rd season partnering together for the annual Home Run Challenge (HRC) to defeat prostate cancer. Since 1996, this campaign has raised more than $47 million to fund prostate cancer research and has helped reduce the U.S. prostate cancer death rate by more than 50% since its inception. All 30 teams participate annually to help raise funds for our cutting-edge research and bring awareness to the journey ahead to defeat prostate cancer.

PCF Chairman Mike Milken shares some pre-game field time with Seattle Mariners outfielder, Ichiro Suzuki and Mariners owner, John Stanton during the 2018 HRC-Seattle tour stop. John has been one of HRC’s strongest supporters since taking over ownership of the Mariners in 2016.

The Shenkman family have supported the Home Run Challenge for years. They joined Mike on-field at Yankee Stadium to cheer on their hometown team.

Mike Milken and his grandchildren join Dodgers owner, Todd Boehly and his family to celebrate Father’s Day and the conclusion of the HRC Tour at Dodger Stadium.
After witnessing the profound effect the Home Run Challenge had, MLB expanded the campaign from 1 week to the entire 3 weeks leading up to Father’s Day. Thanks to this expansion, MLB players hit 530 home runs during the campaign, which resulted in $2.4 million raised through pledges and donations! HRC continues to prove its efficacy in fighting for men and families battling prostate cancer worldwide.

Longtime HRC supporter, Bob Barth is joined by Dodgers legend Tommy Lasorda on the field at Dodger Stadium on Father’s Day.

Mike joins Milwaukee Brewers owner, Mark Attanasio (left) and Wisconsin’s Kohler Company chairman, Herb Kohler (center) at Miller Park for one of the best games of the HRC Tour.
Stephen met his wife Elizabeth in 1990 when they were both working together. There was an instant spark, but they didn’t think much of it at the time since they were both married to other people. Much later, after they had both divorced, Elizabeth moved to Switzerland. “He found me when I moved back to the United States,” says Elizabeth. “This friend of mine calls and says, OK, Steve Eisenmann is going to call you and ask you out on a date; he is so bad at this that you are not going to know that he is asking you out on a date... and you’re so bad at it that you are not going to realize what’s happening. So I’m telling you.”

If you’re the kind of guy who is willing to wait 12 years for a woman, I think it’s safe to say you’re the kind of guy who refuses to give up easily.

So, when Stephen was diagnosed with metastatic prostate cancer in 2016, there was no way he was going down without a fight; “I determined this was a problem to be solved. And at that point, I kind of sat back and I said, ‘Hmm. What’s the first step?’” Stephen used every resource at his disposal, called on friends, and made connections. Eventually, he ended up speaking with PCF CEO Jonathan Simons who recommended he meet with PCF-funded researcher and medical oncologist Dr. Dana Rathkopf at Memorial Sloan Kettering Cancer Center.

Dr. Rathkopf put Stephen on the standard of care at the time – continuous hormone therapy combined with chemotherapy for 6 treatment cycles. Stephen responded to the treatment, and his PSA went down to undetectable. Nevertheless, after about a year, Dr. Rathkopf decided to perform repeat imaging to confirm the response. Despite an undetectable PSA blood test, the imaging showed enlarging lymph nodes. The prostate cancer was back, even though Stephen wasn’t making any PSA. “I said, ‘No big deal,’” recalls Stephen. “‘We’ll just go to the next drug.’”

Unfortunately, it wasn’t that simple. Dr. Rathkopf explained that most current treatments and clinical trials assume that the patient’s cancer cells are making some PSA. Approximately 5% of prostate cancer patients don’t make any PSA, and Stephen was one of them. “There are few trials for men in your situation who don’t make any PSA.”

“When you meet the love of your life so late in life – the whole thing is just like this gut punch,” says Elizabeth, “it was just devastating.” But Dr. Rathkopf, never one to give up either, clarified that while there were few treatment protocols for his cancer, there might be a precision drug. She biopsied his cancer to figure out if there were any genomic markers they could use.
Meanwhile, just days before Stephen’s test results came back, a PCF-funded study out of the University of Michigan found that about 6.9% of prostate cancer patients had a mutation in a gene named CDK12, and that some of those patients had responded to pembrolizumab, an immunotherapy drug that was approved for the treatment of other cancers, but not prostate cancer.

Then the best of the worst of news came in: Stephen had a CDK12 gene mutation marker.

Dr. Rathkopf wanted to give the pembrolizumab immunotherapy a try, but she also wanted Stephen to get a second opinion to ensure that “no stone was left unturned”. She sent him down to Johns Hopkins to see another PCF-funded investigator and medical oncologist, Dr. Emmanuel Antonarakis.

Stephen’s wife was unrelenting in her questioning of Dr. Antonarakis.

Elizabeth asked if all Stephen’s cancer cells made CDK12. Dr. Antonarakis said they did. Elizabeth asked if pembrolizumab killed all cells that made CDK12. Dr. Antonarakis said that it did.

“So, are you telling me he could be cured?” Elizabeth asked. “We don’t use the word cure, we prefer the term complete remission,” said Dr. Antonarakis.

Elizabeth looked at Stephen and said, “Okay honey, we’re going out to celebrate. We got this. You’re going to be cured. I know, it sounds crazy.”

Since all of the patients in the CDK12 Michigan study had prostate cancer that made PSA, the exact treatment protocol for Stephen was not set in stone. He was basically an “N of 1,” as doctors like to say, or his very own clinical trial of one person. They agreed to give Stephen 4 cycles of pembrolizumab, then retest.

But between cycles 2 and 3, Stephen began to feel that his urination had changed. Dr. Rathkopf decided to order another imaging study to evaluate this change, since PSA was not a reliable measure in this case. Stephen was already on his way to his fourth and final treatment the day he missed a call from Memorial Sloan Kettering about his test results.

When Stephen arrived at MSK within the hour, Dr. Rathkopf brought in her whole staff to tell him the news. After only 3 cycles of pembrolizumab, results of his imaging showed a complete response to the treatment.

“The Prostate Cancer Foundation saved my life,” says Stephen, “Dr. Rathkopf saved my life. My wife and my family saved my life. I’m the beneficiary of all that, and I’m the luckiest person in the world.”

Stephen continues to receive pembrolizumab treatments every 3 weeks to keep his prostate cancer at bay. But he doesn’t mind. “I never looked at this like being defeated. My grandkids are a big motivating factor, you know? I want to be there when they get married,” says Stephen. “My father taught me: Never give up. Always fight. Always find a solution.”
How PCF Research and Real-Time Collaboration Saves Men’s Lives

2015

Responding to PCF-FR* (and now Nobel Prize winner) James Allison’s data on checkpoint immune drugs, PCF funds a study at Univ. of Michigan by Dr. Arul Chinnaiyan to explore using genomics in prostate cancer.

Chinnaiyan & Rahr Foundation-PCF team publish their results in Cell, categorizing gene mutations in prostate cancer, among them the CDK12 gene mutation.

2016

Eisenmann is diagnosed with metastatic prostate cancer, despite the fact that he’s making no PSA. His treating physician, PCF YI* Dr. Dana Rathkopf at MSKCC has Eisenmann genetically tested. He has the CDK12 mutation.

PCF-FR Dr. Julie Graff at OHSU applies the result of Chinnaiyan’s work in a small pilot study and begins to see exceptional response for those with CDK12 treated with pembrolizumab.

Although the specifics of Eisenmann’s situation don’t 100% match (because he makes no PSA), Rathkopf sees an opportunity to use PCF unpublished data to treat him with pembrolizumab, since he carries the CDK12 mutation.

Since this is uncharted territory, Rathkopf sends Eisenmann to Johns Hopkins Univ. to meet with PCF YI Dr. Emmanuel Antonarakis for a second opinion. Eisenmann starts on pembrolizumab. The initial plan calls for 4 doses of the drug.

Three treatments into the protocol, Eisenmann’s scans show that he is having a complete response to treatment. The tumors in his lymph nodes had melted away.

PCF YI Dr. Wassim Abida at MSKCC then studies Eisenmann, applies what he learns to patients with other mutations, and publishes in JAMA Oncology.

*PCF-FR = PCF-Funded Researcher
PCF-YI = PCF Young Investigator
PCF Research Awards

PCF advances its research priorities through 3 competitive award types:

- **Challenge Awards** ($1,000,000 and above for 2- to 4-year programs)
  Challenge Awards make large investments in multi-year team science projects that have a high potential for delivering new treatments.

- **Creativity Awards** ($300,000 for 2-year programs)
  Creativity Awards support the development of high-risk, high-reward ideas from established senior scientists.

- **Young Investigator Awards** ($225,000 for 3-year career investment)
  The Young Investigator Awards offer early-career and project support for the ideas of exceptional investigators (generally 35 years old and younger), who are committing their lives to the field of prostate cancer. Their institutions match the award dollar-for-dollar.

- **PCF-VA Center of Excellence Awards**
  In 2016, the PCF committed to invest $50 million over five years to advance precision medicine for America’s veterans. Together, PCF and the U.S. Veterans Administration are building a network of Precision Oncology Centers of Excellence focused on expanding access to genomic sequencing and innovative clinical research.

**Supporting Cures**

There are millions of men currently living with prostate cancer. To support the urgent need for better treatments and cures, the Prostate Cancer Foundation offers individuals and charitable foundations various options for becoming involved and supporting crucial research.

**Donations**

Please mail your check to:

Prostate Cancer Foundation
1250 Fourth Street
Santa Monica, CA 90401

To make an online contribution, please visit our website www.pcf.org

**Blue Ribbon Society**

- Join our elite group of loyal supporters devoted to fostering breakthrough science with a monthly recurring contribution

**Memorial or Tribute Gifts**

- Honor the memory of a loved one or celebrate the accomplishments of a friend or family member by helping others with a tribute gift
- If desired, PCF can also set up a special webpage to honor your loved one and collect donations

**Matching Gifts**

- If your company offers an Employee Matching Gifts program, you can make your hard-earned dollars go twice as far with a matching gift to PCF

**Other Gift Suggestions**

- Gifts of stock
- Support PCF in your estate planning
- Name PCF as a beneficiary of your IRA or life insurance policy
- Federal employees and retirees participating in the Combined Federal Campaign (CFC) can designate PCF as a beneficiary

For more information, visit:
www.pcf.org/donate
2018 Donor Roll

The support of our generous donors makes all that we do at PCF possible. This honor roll acknowledges actual gifts of $1,000 or more, exclusive of pledges, made to PCF during calendar year 2018. We thank you, our friends and supporters, for your continued commitment to PCF’s mission.

$1,000,000-$4,999,999
- Mr. John Barry and Mrs. Daria Becker
- Bernstein Equity Partners LLC
- Blavatnik Family Foundation
- Stein Erik Hagen Allmennytigje Stiftelse
- Milken Family Foundation
- Movember Foundation
- The Stewart J. Rahr Foundation

$500,000-$999,999
- AJA Charitable Fund
- The John Black Charitable Foundation
- Todd Boehly
- Mr. Izzy Englander
- Janssen Research and Development, LLC
- Kern Family Fund
- The San Francisco Foundation
- The Stupski Foundation
- Teach A Man To Fish Foundation

$250,000-$499,999
- Anonymous [2]
- Drew Foundation
- Edward P. Evans Foundation
- Facebook, Inc.
- The Foundation of Man, LTD
- Genzyme, Inc.
- Peter and Laurie Grauer
- Independence Blue Cross
- David G. Kabiller
- Mr. Morris Kahn
- The Morris and Alma Schapiro Fund
- Trailsend Foundation
- The V Foundation for Cancer Research

$150,000-$249,999
- Reina and Emilio Bassini
- Clovis Oncology, Inc.
- The Durden Foundation, Inc. / Mr. Michael Durden / Mrs. Earl Durden
- The Eustace Foundation Trust
- Clay and Lynn Hamlin
- The Katz Family Foundation – Drew Katz
- Howard and Nancy Marks
- Flora and Morris Mizel Foundation II
- Nicklas Family Foundation
- Estate of Calvin Patterson
- Mr. Arthur Rabin
- Ms. Virginia Rinehart
- Mr. and Mrs. Roger Taylor
- WorldQuant Foundation

$100,000-$149,999
- Joseph and Annette Allen
- Amgen, Inc.
- Bayer Healthcare Pharmaceuticals, Inc.
- Dr. Michael M. Berns and Tricia Berns
- The Bill and Ann Bresnan Foundation, Inc.
- Robert & Cynthia Citrone
- Mr. Michael DeAddio
- Eldridge Business Services, LLC
- Mr. Joel Farkas
- Louis and Beth Graziani
- Mr. Kenneth C. Griffin
- i-Future Teens International Foundation
- Mr. and Mrs. Steven B. Kinsky
- Dalia & Larry Leeds/The Leeds Family Foundation
- Major League Baseball Charities, Inc.
- Modell’s Inc.
- Ms. Katherine Moraetis
- Paulson Family Foundation
- Pfizer, Inc.
- The Ressler Family Foundation
- Ms. Alice Rogoff and Mr. David M. Rubenstein
- Mr. Nicholas S. Schorsch
- Mark and Rosalind Shenkman
- Mr. Thomas S. Smith and Ms. Caroline Fitzgibbons
- Jeffrey Tarr, Sr.
- Ted and Dani Virtue
- Weiscom Partners Inc.
- Zisk Family Foundation

$50,000-$99,999
- 1 RFP Limited Partnership
- Anonymous [2]
- Astellas, LLC
- Mark and Debbie Attanasio
- Ron and Judy Baron
- Douglas and Joanne Berry Charitable Fund
- Bristol-Myers Squibb Company
- Arthur and Eva Byrnes
- Casamigos Tequila LLC
- Ray and Patti Chambers
- Collier Capital
- Dendreon Corporation
- Dendreon Pharmaceuticals
- DMIC Holdings Limited
- The Christian Thomas Doerr
- Donnnini-Rudolph Family Foundation
- Eugene and Sallyann Fama
- Mr. Michael Ferro
- Mr. Michael W. Ferro, Jr.
- John R. and Kiendl Dauphinot Gordon Foundation
- Jeffery's & Company, Inc.
- Jordan Industries, Inc
- William P. and Dorian S. Jordan
- William P. and Dorian S. Jordan Foundation, Inc.
- Kissick Family Foundation
- The Laughlin Aldisert Family Fund
- Thomas H. Lee and Ann Tenenbaum
- The Maguire Foundation
- The Milana Family Foundation, Inc.
- R.N. Milikowsky Family Foundation
- Minnesota Twins
- Mr. Thomas P. Nemer
- Progenics Pharmaceuticals, Inc.
- Republic National Distributing Company, LLC
- Michael J. Rinaldi Jr. Revocable Trust
- Cliff and Debbie Robbins and The Robbins Family Foundation
- Marc J. and Carolyn Rowan
- Satter Foundation
- Mr. Ilan Shalit
- Mr. Brian Sheth
- Ms. Lucy Shostak
- Mr. Scott Simon and Mrs. Hillary Simon
- David E. and Jacqueline S. Simon Charitable Foundation
- Mr. Frederick Smith and Mrs. Cheryl L. Smith
- Sun Pharmaceuticals Industries
- Ms. Roxann Taylor
- The Thompson Family Foundation
- The Robert & Jane Toll Foundation
- The Wagner Family Foundation/GoldenTree Asset Management
- Nancy & George Walker Foundation
- Mr. Andrew S. Weinberg
- Mark & Nancy Weinberger Family Foundation
- The Weintraub Family Foundation
- Wild Dunes Men’s Golf Association
- Yurman Family Foundation, Inc.

$25,000-$49,999
- Dr. Eliot Abramowitz
- Mr. and Mrs. William A. Ackman
- Mr. Dwight Anderson
- Anonymous [4]
- Astellas Pharma Global Development, Inc.
- Mr. Duncan Bagshaw and Mrs. Lisa Bagshaw
- The Barth Family Foundation
- The Cecile & Fred Bartman Foundation
- Candice Beaumont
- Sybiel B. Berkman Foundation
- Mr. Benjamin E. Black
- Anthony and Jamie Carr
- Mr. Anthony Carr
- Johnny Carson Foundation
- Mr. John Cefaly
- Ms. Jolene S. Cherry
- Chicago White Sox
- Clark.com
- Jerry and Adriane Cohen
- Mr. Robert D. Collins
- Howard Cox
- Mr. and Mrs. Eric K. Davidson
- Neil and Sandra DeFeo Family Foundation
- Derric’s Day for Prostate Cancer Awareness
- Lea and Marcy Edelson
- Mark and Sally Ein Foundation
- Bethany and Niko Elmaleh
- Endocyte, Inc.
- Faith, Love, Hope, Win Foundation
- Seymour Feldman Foundation, Inc.
- Mr. and Mrs. Sidney Ferenc
- Mr. Jim Filler and Mrs. Carol Filler
- Ralph and Cynthia Finerman
- The Stella Hall & James Fordyce Foundation
- Mr. Emanuel J. Friedman
- Genentech, Inc.
- German Masonic Charitable Foundation
- Mr. Gerald Gibian
- Goldman, Sachs & Co.
- John A. Griffin
- Griffon Corporation
- Nancy and Joel Hart Charitable Foundation
- Sam Herzberg
- Immunomedics Incorporated
- Indigo Auto Group
- Mr. John F. Klein and Mrs. Jennifer A. Klein
- Ms. Elizabeth Kojima
- Ms. Jane Lauder
- Leonard and Evelyn Lauder
- Monica Lester Charitable Trust
- Marc & Jennifer Lipschutz Family Foundation
- Mr. Robert J. Lothenbach
- Mr. Howard Lutnick and Mrs. Allison Lutnick
- Mr. and Mrs. Eric K. Davidson
- Medicine Research Charities
- Jerome Meislin
- Mr. Michael A. Mendelson
Dorothy Phillips Michaud Charitable Trust
Mr. Christian L. Oberbeck and Mrs. Katia Oberbeck
Mr. Robert L. Pike, Jr.
Ms. Robyn Rabin
Rance King Properties, Inc
Redbird Capital Partners
Resilience Management, LLC.
Ronald Rubin
Mr. Arik Ruchim
Sanofi-Aventis
Sempermed USA, Inc.
Mr. Mickey Shapiro
Shostak Charitable Trust
Mr. Ron Sussman
Mr. Steven Tananbaum and Mrs. Lisa Tananbaum
Julie and Bobby Taubman
Tyson Family Foundation
Mr. Vincent L. Verdiramo
Ted and Dani Virtue
The WAF Trust
Mr. George H. Walker and Mrs. Nancy Walker
Estate of Jerry Wasserman
Mrs. Cindy Wolfe

$15,000-$24,999
Mr. Duane Andrews and Mrs. Rebecca Andrews
AstraZeneca
The Elias, Genevieve and Georgina Atol Charitable Trust
Mr. Richard Baker
Roger Barnett
Bellavia Blatt, P.C.
Mr. and Mrs. Seth Bernstein
Mr. Michael A. DeMayo
Credit Suisse Securities (USA) LLC
Mr. David Blado
Ms. Maureen D. Casey
Constellation Pharmaceuticals
Silvercrest Asset Management Group, LLC.
Dr. Edward Loftspring
Mr. Leland Alpert
Advanced Technology Group
Anglers for the Cure
Mr. and Mrs. William Curry
Mr. Ryan E. Barfield
Mr. Joe Banfield
Mr. Michael S. Smith and Mrs. Elizabeth A. Smith
Mr. Howard Chai
Mr. Todd L. Blue
Bonanza Casino
C.A.R.E.
Dr. Eric Campeau
Castellini Foundation
CF Global Trading, LLC
Mr. Howard Chai
Mr. Marvin Chanin and Mrs. Dottie Chanin
Gary Charlesworth
Cherotti Enterprises, Inc.
Mr. David R. Chubon
Cincinnati Reds
Mr. Mitchell Clairfield
Ms. Ramola Daswani
Digital Science Press, Inc.
Stephen Edelmann, Edelmann Family Foundation
Elizabeth Ventura and Stephen Eisenmann
Mr. Peter Fisher
Four Peaks Brewing Co.
FragranceNet
Fuego Box LLC
Mr. Simon Furie and Mrs. Lori Furie
Hartford Foundation for Public Giving
Mr. Mark S. Henderson
Douglas J. Hertz Family Foundation
IBM Employee Services Center
Ms. Julie C. Jaeger
Ms. Ellie Kanner
The Rachel & Drew Katz Foundation, Inc.
Kelsey Family Charitable Fund
Mr. Sven Kjaersgaard
Stacey and Larry Kohl
Herb and Natalie Kohler
Lowell D Kraft & Marc Byron - Trivergence LLC
Mr. Philip Larman
The Thalia & George Liberatos Foundation
Douglas R. Lowe
Mr. and Mrs. Eric Luse
Mr. and Mrs. Paul Madura
Mr. and Mrs. Joan Lee Matloff
F. W. McCarthy Foundation
Mr. William McDaniel
Meadow Club
Memorial Sloan Ketering Cancer Center
Ian Miller
Dr. and Mrs. R. Bruce Montgomery
Jay Moody Memorial Fund
Mr. John G. Morris
Ms. Jennifer Newman
L. Mark Newman Family Foundation
Mr. Mark Nicol
Mrs. Robin Nordhoff
Mr. Victor Pao
Mr. Stephen Paluszek and Mrs. Violeta Paluszek
Paluszek Family Foundation Inc.
Mr. Bradford Peck
Mr. Christian Poehlein
Mr. Daniel Polett and Mrs. Margo Polett
Pros4Care
Mr. Douglas Rachlin
RCM Rise & Shine Memorial
Mr. and Mrs. Jay K. Rosenblatt
Mr. Barry Schlesinger
Mr. Richard L. Schmidt and Mrs. Dorothy A. Schmidt
William and Valerie Schwartz Family Foundation
Mr. Brian Selmo and Mrs. Suzanne Selmo
Mrs. Suzy Shechtman
The Shumway Foundation
Simon Says Run for Prostate Cancer
The Sloan Foundation
Smithsburg Family Foundation
Mr. Carl Sperber
Sweetwater Community, Inc.
Mr. Richard J. Tarlow
Mr. Stephen Tendrich
Terravita Golf Club
The Tuchman Family Foundation
Mr. and Mrs. Michael W. Urbat
Valiance Partners, Inc.
Bradley Walsh
Ms. Sharon Woolman
The Yablon Family Foundation

$10,000-$14,999
A Charity Challenge at Broken Sound Club
Joseph P. Adams, Jr.
Anonymous
Eric Aroesty
Mr. Jeff Assaf and Mrs. Cecelia Assaf
Mr. Joe Banfield
Mr. Jon E. Barfield
B&BST Corporation
Beneficial Bank
Dr. Laurence Blumberg, M.D.
Mr. and Mrs. David C. Brown, Jr.
Courtney and David Corletto
Mr. and Mrs. William Curry
D.E., Inc.
P & M Diaapa Family Foundation
EFF Philanthropies
R.S. Evans Foundation
Galman Family Trust
William D. Gulick Marital Trust
Drs. Kerry Hagen and Kelly Chung
Ms. Shirley Johnson
Stephanie and Ron Kramer
Dr. Suzanne Levine
Dr. Edward Loferspring
The Honorable Earle I. and Carol Mack
The Bill and Jodie Mackintosh Family
Mr. Marlin McKeever
Mr. and Mrs. George A. Mealey
Shmuel Meitar
Mr. Elliott Meyers
Mark and Lisa Neporent Family Foundation
Paramus PBA Local 186
Mr. Evan Sacks
Mr. Sandro Salsano
The San Diego Foundation
Mr. Michael H. Scott
Sheffield Pharmaceuticals
Silvercrest Asset Management Group, LLC.
Skelton Family Fund
Mr. Justin W. Slattery
Mr. William Smith
Mr. Michael S. Smith and Mrs. Elizabeth A. Smith
Will K. Weinstein
Terry L. Wright
Mr. Mark S. Zucker

$5,000-$9,999
AmeriGas Propane
Anonymous [4]
Battle at Bella Vista
Mr. Barak Berkowitz and Ms. Kaori Kuroki
Mr. Keith Bertolino
Mr. Todd L. Blue
Bonanza Casino
C.A.R.E.
Mr. Richard J. Tarlow
Mr. Stephen Paluszek and Mrs. Violeta Paluszek
Paluszek Family Foundation Inc.
Mr. Bradford Peck
Mr. Christian Poehlein
Mr. Daniel Polett and Mrs. Margo Polett
Pros4Care
Mr. Douglas Rachlin
RCM Rise & Shine Memorial
Mr. and Mrs. Jay K. Rosenblatt
Mr. Barry Schlesinger
Mr. Richard L. Schmidt and Mrs. Dorothy A. Schmidt
William and Valerie Schwartz Family Foundation
Mr. Brian Selmo and Mrs. Suzanne Selmo
Mrs. Suzy Shechtman
The Shumway Foundation
Simon Says Run for Prostate Cancer
The Sloan Foundation
Smithsburg Family Foundation
Mr. Carl Sperber
Sweetwater Community, Inc.
Mr. Richard J. Tarlow
Mr. Stephen Tendrich
Terravita Golf Club
The Tuchman Family Foundation
Mr. and Mrs. Michael W. Urbat
Valiance Partners, Inc.
Bradley Walsh
Ms. Sharon Woolman
The Yablon Family Foundation

$2,500-$4,999
Anglers for the Cure
Advanced Technology Group
Mr. Leland Alpert
American Past Time Sports
Anonymous [3]
$1,000-$2,499

4th Annual Santa Cruz Stache Dash
Alden and Elizabeth (Bette) Abraham
Charitable Gift Fund
Mr. Tom Adkin
Stan Adler
Mr. and Mrs. David C. Allen

Alta Data Technologies, LLC
Mr. Richard W. Alvord
Mr. Joe Alwan and Mrs. Mary Ann Alwan
Mr. Denis J. Amato and Mrs. Janice Amato
The Amaturo Family Foundation, Inc.
AmazonSmile Foundation
Mr. Jim Anderson
Anonymous [13]
Mr. Gerald W. Apel and Mrs. Kathleen Apel
Mr. Alan Alger
Arc International North America
Mr. Eliot Amovitz and Mrs. Phyllis Amovitz
Aviation Spectrum Resources, Inc. (ASRI)
AZ State Rifle and Pistol Association - Shotgun Division Blue Ribbon
Clays Tournament
Mr. Moshe Azogui
Jeffrey and Pamela Balton
Paul Baranay
Mr. Thomas E. Beach
Beaver Valley H.O.G.
Fred Bedard
Mr. and Mrs. Richard Beebe
Mr. Joseph Bellmore
Mr. and Mrs. Barry M. Berish
Mr. and Mrs. Saul G. Berkowitz
Mr. and Mrs. Barry Berlin
Mr. John Berman
Mr. Donald B. Berz and Mrs. Janine Berz
BGC Legs
Mr. and Mrs. Fred B. Bialek
Mr. William Biebusch and Mrs. Doreen Biebusch
Mr. Jack Binion
Mr. Robert Blum
Bernt O. Bodal
Mr. and Mrs. Saul G. Berkowitz
Mr. Richard Bogomolny and Ms. Patricia Kozerefski
Mr. Richard Boland and Mrs. Colleen Boland
Dr. and Mrs. Carl W. Bollwinkel
Ms. Heidi Borowiecki
Mr. Bruce Botchman
Mr. Stephen Bowen
Mr. and Mrs. Todd J. Brading
Braman & Associates, Inc.
Mr. Peter E. Braverman
Mr. Eric Braverman
Mr. Michael Bray and Mrs. Barbara Bray
Mr. James Breen
Mr. Dermot Brennan
Mr. Emil J. Britt, Jr.
Ms. Karen Broadnax
Mr. Mark Brooks
Mr. Jono Brown
Mr. Walter W. Brown
Mr. and Mrs. Douglas Brown
Mrs. Deb Brown
Mr. Samuel Brown
David P. and Jerilyn Brownell
Mr. Duane Buehner

Mr. David Bunevich
Craig and Caryn Caffarelli
Mr. Ross Cahn
Mr. Robert Campbell
Carolina Trace Men's Golf Association
Mr. Richard E. Carroll and Mrs. Susan G. Carroll
Mr. Clay Cassel
Castaways Foundation
Mr. Michael Castellano
Castro Village, Inc.
Centennial School District
Mr. Al Ceresa
Mr. James Chao
Mr. Mark M. Chatfield
Mr. C. J. Cheree
David and Suzanne Chomette
Mr. Caspar Chou
Mr. Michael Ciaccia
Ms. Emilia Clarke
Mr. and Mrs. James T. Clarke
Mr. Steve Clough
CNE Direct
Ms. Christine Cole
Ms. Jennifer R. Cole
Mr. and Mrs. Kurt A. Conti
Mr. Clay Cook
Mrs. Tisha Cornwall
Stephen W. Craig Family Foundation
Mr. Bill Crook
Mr. and Mrs. James L. Crothers
Mrs. Doris Crouch
CT Spa Group, LLC
Mr. Laurence Cusick
Mr. Alec Dafferner and Mrs. Elizabeth Dafferner
Mr. Joseph L. D'Amico
Mr. Ross Dargahi
Mr. Carlton Davis
Mr. Jack Devaney
Mr. Barry Didato
Mr. A. W. Dieffenbach, Jr.
Joseph DiNapoli, Sr. Memorial Golf Outing
Mr. and Mrs. E. James Dixon
Mr. Steven L. Dobbelstein
Mr. Gilbert Dodson
Mrs. Julie Dodson Baisinger
DonateWell
Mr. Don Douglas and Mrs. Carolyne Douglas
Mr. Lawrence Downes
Mr. and Mrs. Joseph D. Doyle
Mr. and Mrs. William E. Dreyer
Ms. Tina Driscoll
Mr. Michael Duff and Mrs. Meg Duff
Mr. Matthew Dunham
Michael Dunitz Crisis Foundation
Mr. James Dunn
Mr. and Mrs. Robert J. Dunne III
Mr. Peter J. Durfee
Eagle Group
Mr. and Mrs. James W. Eggenberger
Mr. James Eide
Einhorn Family Charitable Trust
Mrs. Elizabeth Eisenmann
El Conquistador Country Club Men’s Golf Association
Mr. Murray Small and Mrs. Beth Small  
Mr. Frank Smiddy and Mrs. Emily Smiddy  
Mr. Kenneth Smith  
Dr. David Smith  
Mr. Kevin Smith  
Mr. Vern Smith  
Dr. William E. Snowden  
Mr. Loren E. Snyder and Mrs. Deborah Snyder  
Mr. and Mrs. Michael A. Sommer  
Mr. Robert I. Spiegel  
Mr. Murray Stark  
Mr. George Stark  
Mr. Dan Starkey and Mrs. Jenny Starkey  
Cora N. Sternberg, M.D.  
The Samuel & Barbara Sternberg Charitable Foundation  
Mr. Charles Stier  
Mr. John Stodola and Ms. Kathleen Frankle  
Mr. and Mrs. John Strizver  
Ms. Catherine Stupski  
Styles of Steppin’  
Mr. Ronald Styn and Mrs. Susan C. Styn  
Mr. Kevin Sussman  
Mr. and Mrs. Richard Szilasi  
Mr. and Mrs. John Szoke  
Mr. Steven Ta  
Mr. Jeff Taarud  
Mr. Jon Taggett  
Mr. Tony Talbert  
Mr. Michael Tang  
Mr. Richard A. Tanovich  
Ms. Wendy Teramoto  
Steve Tino  
Ms. Marilyn Titus  
Stephen G. Tolchin  
Mr. William Tolstyk and Mrs. Katherine Tolstyk  
Mr. Pascal F. Tone  
Mrs. Teresa Torpey  
Mr. Peter L. Townsend  
Mr. Scott Turban  
Mr. and Mrs. Knight Tuttle  
Mr. James Tyler  
UGI Energy Services, LLC  
Mr. Charles E. Umbarger  
Mr. Robert Urban  
The Urban Electric Company  
Mr. and Mrs. John Veiga  
Mr. Jon Visser and Mrs. Robin Visser  
Dr. and Mrs. Andrew C. von Eschenbach  
Mr. and Mrs. Douglas O. Waikart  
Mr. Timothy R. Wallace  
Mr. and Mrs. Milton J. Walters  
Washington Township Board of Education  
Mr. and Mrs. Charles Wax  
Mr. Eckard Weber  
Michael and Jill Weinstein  
Mr. Steven B. Weinstein  
Dr. Richard E. Weisblatt  
Mr. Paul M. Westbrook  
Mr. and Mrs. Nigel Weston  
Mr. Howard Wheeler  
Martin Wice  
Mr. and Mrs. Harry J. Wild  
Mr. James S. Williams  
Mr. Wayne C. Wilson  
The Wilson Sexton Foundation  
Mr. Chris Witzany  
Mr. Keenan Wolens  
Mr. Jon Wolfe  
Mr. Stanton Wong  
Mr. Roger Wood  
Mr. and Mrs. Bruce Wooley  
Mr. Jan Yarosz  
Mr. and Mrs. Harry Yeaggy  
Mr. Robert Zamarripa  
Mr. Gary Zellerbach  
Mr. Stanley M. Zimmerman and Mrs. Myrna Zimmerman  
Mr. David Zinke  
Mr. Paul Zoisid and Mrs. Aleta Zoidis  

Many vs Cancer Fundraisers  
Participants who raised $1,000 or more  
Greg Abbott  
Andy Aastrachan  
Julie Rose Dodson Baisingter  
Len Bellavia  
Catherine Brown, Styles of Steppin’ Seattle  
Emilia Clarke  
Robert J. Dunne, III  
Keith Fanks, Operation Terminate Prostate Cancer  
Oliver Freund  
Gohill Orthodontics  
The Kiat Family  
Lakeland Bank  
Gideon Lang-Laddie, PROSTATE1000  
Matthew Malczewski  
Steven Malikowski  
Cody Maslatt and the ResearchPoint Global Team  
Jennifer Newman, Simon Says Run for Prostate Cancer  
Orangetheory Fitness Downtown Sunnyside and Morgan Hill  
Paramus PBA Local 186  
Dr. Drew Pinsky  
Prior Lake - Savage Area Schools  
Muhit Rahman  
Melissa Rauch  
Alex Rivas & Robin Bunevich  
David Seewack  
Ramiro Siliezar  
Lisa Silver and The Silver Lining  
Dr. Jonathan and Plum Simons  
Kevin Sussman  
Stephen Tendrich, Pink Nail Society  
Valley HOG Chapter/McMahon’s Harley Davidson  
Washington Township Board of Education  
Tripp Whitbeck  

Blue Ribbon Golf Tournaments  
Golf tournaments that raised $1,000 or more  
4th Annual D-III Father’s Day Weekend GT  
5th Annual 19th Hole Classic  
8th Annual C.A.R.E. Golf Outing  
8th Annual Jay Moody Memorial  
8th Annual Sadie Hawkins GT  
10th Annual Pros4Care - Texas  
12th Annual HLTX Shootout - Texas  
13th Annual FLHW Golf Tournament  
Annual Prostate Cancer Research Invitational  
Battle at Addison Reserve  
Battle at Bella Vista  
Battle at Broken Sound  
Battle at Burlington & Rally for the Cure  
Battle at Herons Glen  
Battle at Katemarya  
Battle at the Meathead Club  
Battle at Palm Beach  
Battle at Pelican Pointe  
Battle at Rarity Bay  
Breakers MGA Event  
California Trace CC MGA Stag Day  
Joseph DiNapoli, Sr. Memorial GT  
DSB Invitational  
El Conquistador Prostate Cancer Tournament  
The Hedge Golf Tournament (Shumway Foundation)  
Lehigh Valley MGA  
Luetzow Charity Golf Outing  
Opening Day Golf Tournament  
Palme Aire Prostate Tournament  
Sheffield Pharma for PC Research  
Sweetwater Mens Cancer Tournament  
University Park Member-Guest for PCF  
Wild Dunes MGA Member/Guest  
Willowbrook RCM Memorial  
Wycliffe CC MGA  

Blue Ribbon Society  
Our community of monthly donors  
Mr. Steve M. Abbott and Mrs. Diana M. Abbott  
Mr. Steven Aberblatt  
Mr. Roy E. Acer  
Mr. Robert M. Agans  
Mr. Larry Allen  
Mr. Mohamed Alhammadi  
Mr. Donald Allen  
Mr. Dean Ambrose and Mrs. Dianne Ambrose  
Mr. Paul N. Anderson  
Mr. Paul Anderson  
Mr. M. Douglas Archer and Mrs. Pat Archer  
Mr. Aaron Bahar  
Mr. Louis A. Baldwin  
Mr. Michael Bankert  
Mr. Mark Bass  
Mr. Donald Beier  
Mr. Dennis E. Bernard  
Mr. John P. Bernier and Mrs. Donna Bernier  
Mr. Michael Bigini  
Mr. Stephen A. Birdsell  
Mrs. DeAnna Blankenship  
Mr. Robert Blum  
Mr. Steve Borowski  
Mr. Laurence Brady  
Mr. and Mrs. Gerald Brenke  
Mr. Robert T. Brew, Jr.  
Ms. Renee Bridges  
Mr. Kelly Brott  
Mr. Grant Brown and Mrs. Sandra Brown  
Mr. Scott C. Brown  
Mr. and Mrs. Stuart Brown  
Mr. Philip Bryan  
Mr. Henry L. Burks and Mrs. Diana Burks  
Ms. Patricia Burton  
Mr. Joe Butler  
Mr. and Mrs. Donald Butts  
Mr. Danny A. Byler and Mrs. Rose Byler  
Mr. Sean Caillias  
Mr. Ernest Campos  
Frank and Adrienne Cardone  
Mr. David P. Carosella  
Mr. William Carr and Mrs. Jean Carr  
Mr. Howard Chai  
Mr. Daniel Chapman  
Mr. Steven Chapman  
Mr. Scott Chaudoir  
Mr. Arthur P. Chimies  
Mr. Graham Church  
Mr. Matthew Cifificiello  
Ms. Dolores Clouser  
Mr. Cory Compton and Mrs. Jacqueline Compton  
Mr. Clay Cook  
Mr. and Mrs. Stephen Cornes  
Mr. Craig J. Couture  
Mr. Bruce Cox  
Mr. Charles E. Cree  
Mr. Edgardo Cruz Martinez  
Mr. Thomas Czajkowski  
Ms. Dorothy Delarm  
Mr. Todd J. Dokken  
Mr. Don Douglas and Mrs. Carolyne Douglas  
Mr. and Mrs. Gary Dummitt  
Ms. Sandra Duncan  
Mr. Willard Easton and Mrs. Joyce Easton  
Eden Formulations  
Mr. Kenneth L. English  
Mr. and Mrs. Daniel J. Feiner  
Mr. Peter Ferrara  
Mr. Carlos Ferrer  
Mr. Tom Fever  
Mr. Arlen J. Fisher  
Mr. Greg Fishwick  
Dr. Rich Fonda  
Mr. Richard Fournier  
Mr. Michael R. Franchio and Mrs. Franchio  
Mr. Max Fuentes
Funds that contributed $1,000 or more

Memorial Tribute Funds

In Memory of:

Nathan Baden
Roddy Brennan
Daniel J. Brown
William G. Bryant
Kent C. Buchner
Ralph Bushnell
Steven P. Caley
Gary Colbert
Stephen S. Cole
Jerry J. Cominso
Larry G. Cornell
Chuck Crist
Moti S. Daswani
Thomas F. Delaney
Jimmy Ray Dieringer
Joseph P. DiNapoli
Bud Dunham
Harry Falber
Stuart Flome
Miles D. Freitag
Edward Gal
Harold Gantz
John G. Gilmour
Sally Goldman
Robert E. Goulding
Leo F. Griffin
Daryl Gross
John Haas

Honorary Tribute Funds

In Honor of:

Elliott Abramowitz
Jason Adams
Andrew J. Astorachan
Adam P. Dicker
R. Christian B. Eveson
Stuart Flome
Harold Gantz
Bob Jee
Gary Lauderdale
Edward Loftspring
Earle I. Mack
Simon McKee
Michael Milken
John Milko
Nelson Money
Bonnie L. Pfeifer Evans
Jonathan W. Simons
Julius H. Zobel

Represents annual donations (gifts, not pledges) between January 1, 2018 and December 31, 2018.
2018 Research Awards
Expanding PCF’s Global Research Enterprise

PCF YOUNG INVESTIGATOR AWARDS
The achievements of PCF Young Investigators represent some of the most game-changing work in all of cancer research. They keep the field of prostate cancer research vibrant with new ideas. In 2018, PCF funded a Foundation record of 29 new Young Investigators. By mid-year 2018, PCF had funded a total of 255 Young Investigators since the program began in 2007.

2018 Paz Littman & Morris Kahn-PCF Young Investigator Award
Saul AlDubayan, MD
Harvard: Dana-Farber Cancer Institute, Boston, MA

2018 Clovis Oncology-PCF Young Investigator Award
Mohammad Asim, PhD
University of Surrey, Surrey, England

2018 Lenny Sands-PCF VAlor Young Investigator Award
Hala Borno, MD
University of California, San Francisco, San Francisco, CA

2018 Jay Jordan-PCF VAlor Young Investigator Award
Frank Cackowski, MD, PhD
University of Michigan, Ann Arbor, MI

2018 Tony D. Minella-PCF VAlor Young Investigator Award
Megan Caram, MD
University of Michigan, Ann Arbor, MI

2018 Todd Boehly-PCF Young Investigator Award
Kellie Cotter, PhD
University of Bern, Bern, Switzerland
2018 Jeremy Coller-PCF Young Investigator Award
Anis Hamid, MBBS
Harvard: Dana-Farber Cancer Institute, Boston, MA

2018 National Cancer Institute-PCF Young Investigator Award
Jennifer Jones, MD, PhD
National Cancer Institute (NCI), Bethesda, MD

2018 John & Daria Barry Foundation-PCF VA lor Young Investigator Award
Salma Kaochar, PhD
Baylor College of Medicine, Houston, TX

2018 Michael & Lori Milken Family Foundation-PCF Young Investigator Award
Sheng-Yu Ku, PhD
Harvard: Dana-Farber Cancer Institute, Boston, MA

2018 John & Daria Barry Foundation-PCF VA lor Young Investigator Award
Hui Li, PhD
University of California, San Francisco, San Francisco, CA

2018 ASTRO-PCF Career Development Award to End Prostate Cancer
Brandon Mahal, MD
Harvard: Dana-Farber Cancer Institute, Boston, MA

2018 Thomas H. Lee-PCF VA lor Young Investigator Award
Danil Makarov, MD
New York University, New York, NY

2018 Thomas Finke-PCF VA lor Young Investigator Award
Megan McNamara, MD
Duke University, Durham, NC

2018 Rebecca and Nathan Milikowsky-PCF Young Investigator Award
Kent Mouw, MD, PhD
Harvard: Dana-Farber Cancer Institute, Boston, MA

2018 James Maguire-PCF Young Investigator Award
Vivek Narayan, MD
University of Pennsylvania, Philadelphia, PA

2018 John & Daria Barry Foundation-PCF VA lor Young Investigator Award
David Oh, MD, PhD
University of California, San Francisco, San Francisco, CA

2018 Foundation 14-PCF Young Investigator Award
Eileen Parkes, MD, PhD
Queen’s University Belfast, Belfast, Northern Ireland

2018 Gina Rinehart-PCF Young Investigator Award
Raquel Perez-Lopez, MD, PhD
Vall d’Hebron Institute of Oncology, Barcelona, Spain

2018 PCF VA lor Young Investigator Award
Year 1 – Keith Frankel
Year 2 – Michael DeAddio
Year 3 – Thomas H. Lee
Sethuramasundaram Pitchiaya, PhD
University of Michigan, Ann Arbor, MI

2018 Seth Bernstein-PCF Young Investigator Award
Nicholas Reder, MD, MPH
University of Washington, Seattle, WA

2018 Igor Tulchinsky-PCF VA lor Young Investigator Award
Zachery Reichert, MD, PhD
University of Michigan, Ann Arbor, MI

2018 Clay Hamlin-PCF Young Investigator Award in Honor of H. Ward Hamlin, Jr.
Veronica Rodriguez-Bravo, PhD
Thomas Jefferson University, Philadelphia, PA

2018 Michael & Lori Milken Family Foundation-PCF Young Investigator Award
Joshua Russo, MD, PhD
Harvard: Beth Israel Deaconess Medical Center, Boston, MA

2018 Larry Ruvo-PCF Young Investigator Award
Adam Sharp, MD, PhD
Institute of Cancer Research, The Royal Marsden Hospital, London, England

2018 PCF Young Investigator Award in Honor of Selma Rabin
Min Yuen Teo, MD
Memorial Sloan Kettering Cancer Center, New York, NY

2018 Seth Bernstein-PCF Young Investigator Award
Vasanth Viswanathan, PhD
Broad Institute of MIT & Harvard, Cambridge, MA

2018 National Cancer Institute-PCF Young Investigator Award
Scott Wilkinson, PhD
National Cancer Institute, Bethesda, MD

2018 John & Daria Barry Foundation-PCF VA lor Young Investigator Award
David Wise, MD, PhD
New York University, New York, NY

2016 Michael DeAddio-PCF Young Investigator Award (Funding Year 3 of 3)
Alastair Davies, PhD
University of British Columbia, Vancouver, BC

2016 Adrianne and Jerry Cohen-PCF Young Investigator Award (Funding Year 3 of 3)
Eleonora Dondossola, PhD
The University of Texas MD Anderson Cancer Center, Houston, TX

All PCF Young Investigators present at the 25th Annual PCF Scientific Retreat
PCF CHALLENGE AWARDS

In 2018, 20 Challenge Award teams were funded by the Foundation. Through peer reviews, PCF selected these projects out of 70 proposals from highly qualified research teams at 48 prestigious cancer centers located in 9 countries. The Class of 2018 Challenge Awards represents an investment of nearly $17 million in advanced prostate cancer research.

2018 Movember Foundation–PCF Challenge Awards

Co-Principal Investigators:
Mark Pomerantz, MD
Harvard: Dana-Farber Cancer Institute, Boston, MA
Philip Kantoff, MD
Memorial Sloan Kettering Cancer Center, New York, NY
Goal: To determine the prevalence and prognostic significance of inherited DNA Damage Repair gene alterations in high-risk localized prostate cancer, and model the impact of germline screening and risk-tailored management in this population

2018 Movember Foundation–PCF VAlor Challenge Award

Co-Principal Investigators:
Julie Graff, MD
VA Portland Healthcare System, Portland, OR
Amy Moran, PhD
Oregon Health & Science University, Portland, OR
Karen Sfanos, PhD
Johns Hopkins University, Baltimore, MD
Goal: To conduct a clinical trial testing a therapy targeting TROP-2 and develop biomarkers to select patients likely to benefit

2018 Movember Foundation–PCF VAlor Challenge Award

Co-Principal Investigators:
Steven Patierno, PhD
Duke University, Durham, NC
Daniel George, MD
Duke University, Durham, NC
Jennifer Freedman, PhD
Duke University, Durham, NC
Jiaoti Huang, MD, PhD
Duke University, Durham, NC
Amanda Hargrove, PhD
Duke University, Durham, NC
Goal: To determine whether altered RNA splicing drives more aggressive prostate cancer in African American men, and the therapeutic potential for targeting this biology

2018 PCF Challenge Awards

Co-Principal Investigators:
Emmanuel Antonarakis, MD
Johns Hopkins University, Baltimore, MD
Sushant Kachhap, PhD
Johns Hopkins University, Baltimore, MD
Goal: To evaluate the efficacy of bipolar androgen therapy followed by immunotherapy in advanced prostate cancer patients, and define biomarkers and mechanisms of response
Award Donor: The Morris & Alma Schapiro Fund

Co-Principal Investigators:
Steven Balk, MD, PhD
Harvard: Beth Israel Deaconess Medical Center, Boston, MA
Huihui Ye, MD
Harvard: Beth Israel Deaconess Medical Center, Boston, MA
David Avigan, MD
Harvard: Beth Israel Deaconess Medical Center, Boston, MA
Gordon Freeman, PhD
Harvard: Dana-Farber Cancer Institute, Boston, MA
Goal: To identify intermediate clinical endpoints that reliably predict overall survival in men with metastatic hormone sensitive prostate cancer, in order to speed and improve clinical trials

Co-Principal Investigators:
George Coukos, MD, PhD
University of Lausanne, Lausanne, Switzerland
Mark Rubin, MD
University of Bern, Bern, Switzerland
Goal: To investigate whether radiation therapy can improve responses to checkpoint immunotherapy in prostate cancer, and develop biomarkers to identify patients likely to benefit from this combination
Award Donor: Stewart J. Rahr Foundation

Co-Principal Investigators:
Claire Fletcher, PhD
Imperial College London, London, England
Charlotte Bevan, PhD
Imperial College London, London, England
Goal: To determine whether the genome-protecting RNA NORAD may serve as a new treatment target and as a biomarker to predict treatment responses
Award Donor: John Black Charitable Foundation

Co-Principal Investigators:
Rakesh Heer, MBBS, PhD
Newcastle University, Newcastle upon Tyne, England
Luke Gaughan, PhD
Newcastle University, Newcastle upon Tyne, England
Goal: To develop a prostate cancer organoid model system that recreates tumor mutations from individual patients and aids in selecting precision medicine treatments
Award Donors: John Black Charitable Foundation, John Drew
Co-Principal Investigators:
Philip Kantoff, MD
Memorial Sloan Kettering Cancer Center, New York, NY
Lorelei Mucci, ScD, MPH
Harvard T.H. Chan School of Public Health, Boston, MA
Ellie Papaemmanuil, PhD
Memorial Sloan Kettering Cancer Center, New York, NY
Michael Berger, PhD
Memorial Sloan Kettering Cancer Center, New York, NY
Ross Levine, MD
Memorial Sloan Kettering Cancer Center, New York, NY

**Goal:** To determine whether clonal hematopoiesis, a condition characterized by the accumulation of mutations in blood cells, promotes worse outcomes in prostate cancer patients and influences the efficacy or toxicity of treatments
**Award Donor:** Anonymous

---

Co-Principal Investigators:
Aaron LeBeau, PhD
University of Minnesota, Minneapolis, MN
Brandon Moriarty, PhD
University of Minnesota, Minneapolis, MN
Charles Ryan, MD
University of Minnesota, Minneapolis, MN
Todd DeFor, MS
University of Minnesota, Minneapolis, MN
Jeffrey Miller, MD
University of Minnesota, Minneapolis, MN

**Goal:** To develop a novel CD133-targeted NK cell immunotherapy for the treatment of aggressive variant prostate cancer
**Award Donors:** Anonymous, The Lawrence R. Souza Revocable Living Trust, Foundation 14

---

Co-Principal Investigators:
Douglas McNeel, MD, PhD
University of Wisconsin, Madison, WI
Jamey Weichert, PhD
University of Wisconsin, Madison, WI

**Goal:** To investigate the efficacy of combining checkpoint immunotherapy, anti-tumor vaccines, and targeted radionuclide therapy for the treatment of prostate cancer
**Award Donors:** Janssen Pharmaceuticals and anonymous donor

---

Principal Investigators:
Kenneth Pienta, MD
Johns Hopkins University, Baltimore, MD
Johann de Bono, MD, PhD
Institute of Cancer Research, The Royal Marsden Hospital, London, England
Peter Kuhn, PhD
University of Southern California, Los Angeles, CA
Bruce Trock, PhD, MPH
Johns Hopkins University, Baltimore, MD
Tamara Lotan, MD
Johns Hopkins University, Baltimore, MD
Jun Luo, PhD
Johns Hopkins University, Baltimore, MD

**Goal:** To develop biomarkers for early identification of prostate cancer patients at risk for lethal disease and determine the steps by which prostate cancer metastasizes
**Award Donors:** David Fleisher and various other donors

---

2018 PCF VA lor Challenge Awards

Co-Principal Investigators:
Thomas Hope, MD
University of California, San Francisco, San Francisco, CA
Matthew Rettig, MD
University of California, Los Angeles, Los Angeles, CA
Michael Morris, MD
Memorial Sloan Kettering Cancer Center, New York, NY
Matthias Eiber, MD
Technical University of Munich, Munich, Germany

**Goal:** To determine factors associated with response to PSMA-targeted radionuclide therapy and improve selection of patients most likely to benefit from this treatment
**Award Donors:** Peter Grauer, Michael Berns, Michael DeAddio, Randy King

---

2018 PCF Special Challenge Awards

Co-Principal Investigators:
Howard Scher, MD
Memorial Sloan Kettering Cancer Center, New York, NY
Dana Tsui, PhD
Memorial Sloan Kettering Cancer Center, New York, NY
Patrick Erdman, DO
Memorial Sloan Kettering Cancer Center, New York, NY

**Goal:** To investigate the impact of various blood collection methods and patient factors on results from liquid biopsy tests in order to accelerate the development of prostate cancer precision medicine tests that can be used in routine practice settings
**Award Donor:** Stewart J. Rahr Foundation

---

PCF AttackJAK Special Challenge Award

Principal Investigator:
Ross Levine, MD
Memorial Sloan Kettering Cancer Center, New York, NY

**Goal:** Development and validation of JAK2 kinase inhibitors as a novel cancer treatment
**Award Donor:** Arthur Kern

---

The ICECaP Initiative: Assessment of Intermediate Clinical Endpoints

Principal Investigator:
Christopher Sweeney, MBBS
Harvard: Dana-Farber Cancer Institute

**Goal:** To identify intermediate clinical endpoints that serve as reliable surrogates for overall survival in localized prostate cancer clinical trials in order to accelerate the development of new treatments for these patients
**Award Donors:** Dendreon and Sanofi Genzyme

---

Co-Principal Investigators:
Ganesh Raj, MD, PhD
University of Texas Southwestern Medical Center, Dallas, TX
Xiankai Sun, PhD
University of Texas Southwestern Medical Center, Dallas, TX

**Goal:** To develop novel drugs for neuroendocrine prostate cancer which can simultaneously be used for both imaging and treatment
**Award Donors:** The Lawrence R. Souza Revocable Living Trust, Jeff Zisk
PCF VALOR PRECISION ONCOLOGY CENTER OF EXCELLENCE AWARDS

As of October 2018, 10 Precision Oncology Centers of Excellence were funded by the Foundation through PCF’s now 2-year partnership with the U.S. Veterans Administration. The Class of 2018 PCF-VALor Centers of Excellence Awards represents a commitment of $25.5 million over 5 years to provide U.S. veterans with the same or better precision oncology care and the same access to clinical trials as our most fortunate private citizens.

The 2018 Stewart J. Rahr Foundation Precision Oncology Center of Excellence Award
Principal Investigator:
Ajjai Alva, MD
VA Ann Arbor Healthcare System / University of Michigan, Ann Arbor, MI

The Blavatnik Family Foundation Precision Oncology Center of Excellence Award
Principal Investigator:
Antonio Fojo, MD, PhD
James J. Peters VA Medical Center / Columbia University Medical Center, Bronx, NY

The Robert Frederick Smith Precision Oncology Center of Excellence Award
Principal Investigator:
Joshua Meeks, MD, PhD
Jesse Brown VA Medical Center / Northwestern University, Chicago, IL

The Stephen J. Cloobeck Precision Oncology Center of Excellence Award
Principal Investigator:
Robert Bruce Montgomery, MD
VA Puget Sound Health Care System / University of Washington, Seattle, WA

The John and Daria Barry Foundation Precision Oncology Center of Excellence Award
Principal Investigator:
Kosj Yamoah, MD, PhD
VA Sunshine Healthcare Network, Tampa, FL / H. Lee Moffitt Cancer Center & Research Institute, St. Petersburg, FL

The Lori and Michael Milken Family Foundation Precision Oncology Center of Excellence Award
Principal Investigator:
Matthew Rettig, MD
VA West Los Angeles Medical Center / University of California, Los Angeles, Los Angeles, CA

The Trailsend Foundation and Elaine Wynn Precision Oncology Center of Excellence Award
Principal Investigator:
Megan McNamara, MD
Durham VA Medical Center / Duke University, Durham, NC

The Andy Astrachan and Marc Utay Precision Oncology Center of Excellence Award
Principal Investigators:
Kyle Robinson, MD
Corporal Michael J. Crescenz VA Medical Center / University of Pennsylvania, Philadelphia, PA
Nevena Damjanov, MD
Corporal Michael J. Crescenz VA Medical Center / University of Pennsylvania, Philadelphia, PA
ANNUAL PCF WOMEN IN SCIENCE FORUM

The Prostate Cancer Foundation is acknowledging the amazing contributions that women have made in the field of science and medicine, specifically in prostate cancer research.

Before PCF began to encourage prostate cancer researchers by funding their early careers, the numbers of women in the field were few. Through our Young Investigator Awards and team science Challenge Awards programs, PCF has helped to increase the number of women who are building a long-term career in prostate cancer research.

“The Prostate Cancer Foundation has really led the effort in supporting women in science,” said PCF Young Investigator Stacy Loeb, MD, of New York University.

The prostate cancer field has historically been male-dominated. Beginning in 2016, in recognition of career issues unique to women, three female PCF-funded investigators, Drs. Karen Knudsen, PhD (Thomas Jefferson University), Lorelei Mucci, ScD (Harvard School of Public Health), and Himisha Beltran, MD (Weill Cornell Medicine), organized a PCF Women in Science Forum at PCF’s Annual Scientific Retreat, to which all female (and any interested male) attendees are invited to attend. The goals of the Forum are to create a network of PCF-funded women scientists, to team-build through discussion and social events, to ensure a strong pipeline of female prostate cancer researchers and clinicians, and to identify opportunities for further training, mentoring, and synergy of a stellar network of female prostate cancer researchers and clinicians.
## Consolidated Statement of Financial Position

<table>
<thead>
<tr>
<th>December 31</th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>2018 Total</th>
<th>2017 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and Cash Equivalents</td>
<td>$16,044,813</td>
<td>$4,650,000</td>
<td>$20,694,813</td>
<td>$24,166,964</td>
</tr>
<tr>
<td>Pledges Receivable (Net)</td>
<td>14,894,136</td>
<td>12,725,000</td>
<td>27,619,136</td>
<td>27,596,425</td>
</tr>
<tr>
<td>Prepaid Expenses and Other Assets</td>
<td>1,009,073</td>
<td>-</td>
<td>1,009,073</td>
<td>1,135,934</td>
</tr>
<tr>
<td>Property and Equipment (Net)</td>
<td>1,660,133</td>
<td>-</td>
<td>1,660,133</td>
<td>1,865,740</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$33,608,155</strong></td>
<td><strong>$17,375,000</strong></td>
<td><strong>$50,983,155</strong></td>
<td><strong>$54,765,063</strong></td>
</tr>
<tr>
<td><strong>LIABILITIES AND NET ASSETS</strong></td>
<td><strong>$33,608,155</strong></td>
<td><strong>$17,375,000</strong></td>
<td><strong>$50,983,155</strong></td>
<td><strong>$54,765,063</strong></td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts Payable</td>
<td>$783,154</td>
<td>-</td>
<td>$783,154</td>
<td>$1,319,780</td>
</tr>
<tr>
<td>Accrued Liabilities</td>
<td>2,298,474</td>
<td>-</td>
<td>2,298,474</td>
<td>1,916,705</td>
</tr>
<tr>
<td>Deferred Revenue</td>
<td>50,000</td>
<td>-</td>
<td>50,000</td>
<td>100,000</td>
</tr>
<tr>
<td>Grants Payable</td>
<td>22,589,282</td>
<td>-</td>
<td>22,589,282</td>
<td>22,612,846</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>25,720,910</strong></td>
<td><strong>-</strong></td>
<td><strong>25,720,910</strong></td>
<td><strong>25,949,331</strong></td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without Donor Restrictions</td>
<td>7,887,245</td>
<td>-</td>
<td>7,887,245</td>
<td>17,982,398</td>
</tr>
<tr>
<td>With Donor Restrictions</td>
<td>-</td>
<td>17,375,000</td>
<td>17,375,000</td>
<td>10,833,334</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>7,887,245</strong></td>
<td><strong>17,375,000</strong></td>
<td><strong>25,262,245</strong></td>
<td><strong>28,815,732</strong></td>
</tr>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td><strong>$33,608,155</strong></td>
<td><strong>$17,375,000</strong></td>
<td><strong>$50,983,155</strong></td>
<td><strong>$54,765,063</strong></td>
</tr>
</tbody>
</table>
# PROSTATE CANCER FOUNDATION
## Consolidated Statement of Activities

### Year Ended December 31

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>2018 Total</th>
<th>2017 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue and Public Support</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants and Contributions</td>
<td>$ 28,693,134</td>
<td>$ 13,375,000</td>
<td>$ 42,068,134</td>
<td>$ 44,056,615</td>
</tr>
<tr>
<td>Interest and Dividends</td>
<td>232,741</td>
<td></td>
<td>232,741</td>
<td>88,679</td>
</tr>
<tr>
<td>Other Income (Loss)</td>
<td>(274,082)</td>
<td></td>
<td>(274,082)</td>
<td>(327,539)</td>
</tr>
<tr>
<td>Net Assets Released from</td>
<td>6,833,334</td>
<td>(6,833,334)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Donor Restrictions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Revenue and Public Support</strong></td>
<td>$35,485,127</td>
<td>$6,541,666</td>
<td>$42,026,793</td>
<td>$43,817,755</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program Services:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research Grants</td>
<td>28,275,948</td>
<td></td>
<td>28,275,948</td>
<td>27,813,385</td>
</tr>
<tr>
<td>Compensation, Benefits, and Payroll Taxes</td>
<td>3,972,609</td>
<td></td>
<td>3,972,609</td>
<td>3,772,146</td>
</tr>
<tr>
<td>Global Scientific Conferences, Unpublished Data, and Knowledge Exchanges</td>
<td>2,091,212</td>
<td></td>
<td>2,091,212</td>
<td>1,991,482</td>
</tr>
<tr>
<td>Professional Fees</td>
<td>895,647</td>
<td></td>
<td>895,647</td>
<td>778,077</td>
</tr>
<tr>
<td>Outreach, Events, and Meetings</td>
<td>882,407</td>
<td></td>
<td>882,407</td>
<td>369,934</td>
</tr>
<tr>
<td>Media, Public Relations, and Publications</td>
<td>7,88,133</td>
<td></td>
<td>7,88,133</td>
<td>941,673</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>466,852</td>
<td></td>
<td>466,852</td>
<td>380,396</td>
</tr>
<tr>
<td>Travel, Meals, and Entertainment</td>
<td>335,641</td>
<td></td>
<td>335,641</td>
<td>265,805</td>
</tr>
<tr>
<td>Office Expenses</td>
<td>228,654</td>
<td></td>
<td>228,654</td>
<td>204,113</td>
</tr>
<tr>
<td>Occupancy</td>
<td>180,390</td>
<td></td>
<td>180,390</td>
<td>16.574</td>
</tr>
<tr>
<td><strong>Total Program Services</strong></td>
<td>$38,117,493</td>
<td></td>
<td>$38,117,493</td>
<td>$36,882,085</td>
</tr>
<tr>
<td><strong>Supporting Services:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and General:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compensation, Benefits, and Payroll Taxes</td>
<td>1,983,550</td>
<td></td>
<td>1,983,550</td>
<td>1,997,020</td>
</tr>
<tr>
<td>Office Expenses</td>
<td>858,766</td>
<td></td>
<td>858,766</td>
<td>720,302</td>
</tr>
<tr>
<td>Professional Fees</td>
<td>411,229</td>
<td></td>
<td>411,229</td>
<td>380,360</td>
</tr>
<tr>
<td>Occupancy</td>
<td>164,525</td>
<td></td>
<td>164,525</td>
<td>164,195</td>
</tr>
<tr>
<td>Travel, Meals, and Entertainment</td>
<td>72,596</td>
<td></td>
<td>72,596</td>
<td>119,105</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>71,296</td>
<td></td>
<td>71,296</td>
<td>30,533</td>
</tr>
<tr>
<td>Media, Public Relations, and Publications</td>
<td>30,073</td>
<td></td>
<td>30,073</td>
<td>48,268</td>
</tr>
<tr>
<td>Other Expenses</td>
<td>-</td>
<td></td>
<td>-</td>
<td>30,000</td>
</tr>
<tr>
<td><strong>Total Management and General:</strong></td>
<td>$3,592,035</td>
<td></td>
<td>$3,592,035</td>
<td>$3,489,703</td>
</tr>
<tr>
<td><strong>Fundraising:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outreach, Events, and Meetings</td>
<td>1,659,027</td>
<td></td>
<td>1,659,027</td>
<td>2,683,645</td>
</tr>
<tr>
<td>Travel, Meals, and Entertainment</td>
<td>1,109,413</td>
<td></td>
<td>1,109,413</td>
<td>1,315,149</td>
</tr>
<tr>
<td>Compensation, Benefits, and Payroll Taxes</td>
<td>532,810</td>
<td></td>
<td>532,810</td>
<td>529,659</td>
</tr>
<tr>
<td>Office Expenses</td>
<td>380,177</td>
<td></td>
<td>380,177</td>
<td>361,721</td>
</tr>
<tr>
<td>Professional Fees</td>
<td>157,198</td>
<td></td>
<td>157,198</td>
<td>251,281</td>
</tr>
<tr>
<td>Occupancy</td>
<td>22,322</td>
<td></td>
<td>22,322</td>
<td>35,376</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>8,682</td>
<td></td>
<td>8,682</td>
<td>2,256</td>
</tr>
<tr>
<td>Media, Public Relations, and Publications</td>
<td>1,123</td>
<td></td>
<td>1,123</td>
<td>3,999</td>
</tr>
<tr>
<td><strong>Total Fundraising:</strong></td>
<td>$3,870,752</td>
<td></td>
<td>$3,870,752</td>
<td>$5,183,086</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>$45,580,280</td>
<td></td>
<td>$45,580,280</td>
<td>$45,354,874</td>
</tr>
<tr>
<td><strong>Change in Net Assets</strong></td>
<td>(10,095,153)</td>
<td>6,541,666</td>
<td>(3,553,487)</td>
<td>(1,537,119)</td>
</tr>
<tr>
<td>Net Assets – Beginning Year</td>
<td>17,982,398</td>
<td>10,833,334</td>
<td>28,815,732</td>
<td>30,352,851</td>
</tr>
<tr>
<td>Net Assets – End of Year</td>
<td>$ 7,887,245</td>
<td>$17,375,000</td>
<td>$25,262,245</td>
<td>$28,815,732</td>
</tr>
</tbody>
</table>
## Consolidated Statement of Cash Flows

### Year Ended December 31

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in Net Assets</td>
<td>$(3,553,487)</td>
<td>$(1,537,119)</td>
</tr>
</tbody>
</table>

**Adjustments to Reconcile Change in Net Assets to Net Cash Used In Operating Activities:**

- Uncollectible Pledges Receivable: - 30,000
- Change in Present Value Discount on Pledges Receivable: 415,854 94,086
- Depreciation and Amortization: 546,830 413,205

**Increase (Decrease) in:**

- Pledges Receivable: (438,565) 730,535
- Prepaid Expenses and Other Assets: 126,861 (932,453)
- Accounts Payable: (536,626) 589,198
- Accrued Liabilities: 381,769 552,179
- Deferred Revenue: (50,000) (100,000)
- Grants Payable: (23,564) 2,170,608

**Net Cash Provided by (Used In) Operating Activities:**

- $(3,130,928) 2,010,239

**CASH FLOWS USED IN INVESTING ACTIVITIES:**

- Purchase of Property and Equipment: (341,223) (1,569,207)

**Net Increase/(Decrease) in Cash and Cash Equivalents:**

- $(3,472,151) 441,032

**Cash and Cash Equivalents – Beginning of Year:**

- 24,166,964 23,725,932

**Cash and Cash Equivalents – End of Year:**

- $20,694,813 $24,166,964
To the Board of Directors
Prostate Cancer Foundation

Report on the Consolidated Financial Statements
We have audited the accompanying consolidated financial statements of the Prostate Cancer Foundation, which comprise the consolidated statement of financial position as of December 31, 2018, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Consolidated Financial Statements
Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility
Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Prostate Cancer Foundation as of December 31, 2018, and the changes in its consolidated net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Report on Summarized Comparative Information
We have previously audited Prostate Cancer Foundation’s 2017 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated August 15, 2018. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2017 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

Green Hasson & Janks LLP
April 8, 2019
Los Angeles, California
2018 Supporting Partners

PCF is grateful for our corporate supporters. Contributions and campaigns from these organizations are enabling PCF to move closer to a world without prostate cancer.
### Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Milken</td>
<td>Founder and Chairman, Prostate Cancer Foundation</td>
</tr>
<tr>
<td>Andrew J. Astrachan</td>
<td>Chief Executive Officer, Onyx Partners, Inc.</td>
</tr>
<tr>
<td>Emilio Bassini</td>
<td>Managing Principal, Bassini &amp; Company</td>
</tr>
<tr>
<td>James C. Blair, PhD</td>
<td>Partner, Domain Associates, LLC</td>
</tr>
<tr>
<td>Steven A. Burd</td>
<td>Founder and Chief Executive Officer, Burd Health LLC</td>
</tr>
<tr>
<td>Neil P. DeFeo</td>
<td>Executive Partner, Nonantum Capital Partners</td>
</tr>
<tr>
<td>David A. Ederer</td>
<td>Chairman, Ederer Investment Company</td>
</tr>
<tr>
<td>Jonathan Evans</td>
<td>President, Evans &amp; Co., LLC</td>
</tr>
<tr>
<td>R. Christian B. Evensen</td>
<td>Managing Partner, Flintridge Capital Investments, LLC</td>
</tr>
<tr>
<td>Peter T. Grauer</td>
<td>Chairman, Bloomberg LP</td>
</tr>
<tr>
<td>The Reverend Rosey Grier</td>
<td>Milken Family Foundation</td>
</tr>
<tr>
<td>Stein Erik Hagen</td>
<td>Chairman, Orkla ASA</td>
</tr>
<tr>
<td>Stuart Holden, MD</td>
<td>Clinical Professor of Urology, David Geffen School of Medicine, Spielberg Family Chair of Urologic Oncology, Associate Director, UCLA Institute of Urologic Oncology</td>
</tr>
<tr>
<td>Clark Howard</td>
<td>Syndicated TV and Radio Host</td>
</tr>
<tr>
<td>Arthur H. Kern</td>
<td>Investor</td>
</tr>
<tr>
<td>David H. Koch</td>
<td>Board Director, Koch Industries, Inc.</td>
</tr>
<tr>
<td>The Honorable Earl I. Mack</td>
<td>Senior Partner, The Mack Company</td>
</tr>
<tr>
<td>Shmuel Meitar</td>
<td>Chairman and Founder, Aurec Capital</td>
</tr>
<tr>
<td>Lori Milken</td>
<td>Vice President, Prostate Cancer Foundation</td>
</tr>
<tr>
<td>Christopher J. Moran</td>
<td>Chairman, Moran Group of Companies, Co-Operation Ireland</td>
</tr>
<tr>
<td>Henry L. Nordhoff</td>
<td>Chairman and Chief Executive Officer, Banyan Biomarkers, Inc.</td>
</tr>
<tr>
<td>Drew Pinsky, MD</td>
<td>Internist, Addictionologist, Radio and Television Host</td>
</tr>
<tr>
<td>Lynda Resnick</td>
<td>Vice Chairman, The Wonderful Company</td>
</tr>
<tr>
<td>Neal I. Rodin</td>
<td>Chairman, International Financial Company, LLC</td>
</tr>
<tr>
<td>Jason J. Safriet</td>
<td>Managing Director, Head of Security Sales Credit Suisse</td>
</tr>
<tr>
<td>Richard V. Sandler</td>
<td>Partner, Maron &amp; Sandler, Executive Vice President, Milken Family Foundation</td>
</tr>
<tr>
<td>Paul Villanti</td>
<td>Executive Director, Programs, Movember Foundation</td>
</tr>
<tr>
<td>Andrew C. von Eschenbach, MD</td>
<td>President, Samaritan Health Initiatives Inc., Former Commissioner, Food and Drug Administration, Former Director, National Cancer Institute, Senior Fellow, Milken Institute</td>
</tr>
<tr>
<td>Kneeland Youngblood, MD</td>
<td>Founding Partner, Pharos Capital Group</td>
</tr>
<tr>
<td>Jeff Zisk</td>
<td>Managing Director, Surrey Ventures</td>
</tr>
</tbody>
</table>

### Leadership Team

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan W. Simons, MD</td>
<td>President and Chief Executive Officer</td>
</tr>
<tr>
<td>Ralph Finerman</td>
<td>Chief Financial Officer, Treasurer, and Secretary</td>
</tr>
<tr>
<td>Howard R. Soule, PhD</td>
<td>Executive Vice President, Chief Science Officer</td>
</tr>
<tr>
<td>Stuart Holden, MD</td>
<td>Medical Director</td>
</tr>
<tr>
<td>Christine N. Jones</td>
<td>Chief Operating Officer</td>
</tr>
<tr>
<td>Helen Hsieh</td>
<td>Senior Vice President, Finance and Administration</td>
</tr>
<tr>
<td>Ed Dean</td>
<td>Vice President, Corporate Development</td>
</tr>
<tr>
<td>Benjamin Engel</td>
<td>Vice President, Development Operations</td>
</tr>
<tr>
<td>Jan Haber</td>
<td>Vice President, Events</td>
</tr>
<tr>
<td>Julie DiBiase</td>
<td>Vice President, Content</td>
</tr>
<tr>
<td>Colleen McKenna</td>
<td>Vice President, Communications and Public Relations</td>
</tr>
<tr>
<td>Rebecca Levine</td>
<td>Chief of Staff, Vice President, Government Affairs</td>
</tr>
<tr>
<td>Kathryn Schwertfeger</td>
<td>General Counsel</td>
</tr>
</tbody>
</table>
James Allison, PhD, chair of Immunology and executive director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center, was awarded the 2018 Nobel Prize in Physiology or Medicine for launching an effective new way to attack cancer by treating the immune system rather than the tumor. The prize recognizes Allison’s basic science discoveries on the biology of T cells, the adaptive immune system’s soldiers, and his invention of immune checkpoint blockade to treat cancer.

PCF is extremely proud to have provided crucial, initial funding for Dr. Allison’s early prostate cancer immunotherapy research.

The Nobel Prize in Physiology or Medicine has been awarded 108 times to 214 Nobel Laureates between 1901 and 2017.